Archives

Human Trafficking: Pharmacy’s Impact on Care

Learning Objectives

 

After completing this application-based continuing education activity, pharmacists will be able to

  • Review the history and current laws of human trafficking in the United States
  • Recognize common terms, warning signs, and/or vulnerabilities for human trafficking in pharmacy patients/customers
  • Describe pharmacists’ impact on identifying and supporting victims and survivors of human trafficking
  • Ensure proper referral, treatment, and counseling for common health risks associated with human trafficking

After completing this application-based continuing education activity, pharmacy technicians will be able to

  • Review the history and current laws of human trafficking in the United States
  • Recognize common terms, warning signs, and/or vulnerabilities for human trafficking in pharmacy patients/customers
  •  Identify signs/signals of human trafficking red flags to notify pharmacists or law enforcement

Bar code with human silhouettes in between

 

Release Date: March 1, 2023

Expiration Date: March 1, 2026

Course Fee

Pharmacist $7

Technician $4

There is no grant funding for this CE activity

ACPE UANs

Pharmacist: 0009-0000-23-006-H99-P

Pharmacy Technician: 0009-0000-23-006-H99-T

Session Codes

Pharmacist:  23YC06-KAB48

Pharmacy Technician:  23YC06-BAX92

Accreditation Hours

2.0 hours of CE

Accreditation Statements

The University of Connecticut School of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.  Statements of credit for the online activity ACPE UAN 0009-0000-23-006-H99-P/T  will be awarded when the post test and evaluation have been completed and passed with a 70% or better. Your CE credits will be uploaded to your CPE monitor profile within 2 weeks of completion of the program.

 

Disclosure of Discussions of Off-label and Investigational Drug Use

The material presented here does not necessarily reflect the views of The University of Connecticut School of Pharmacy or its co-sponsor affiliates. These materials may discuss uses and dosages for therapeutic products, processes, procedures and inferred diagnoses that have not been approved by the United States Food and Drug Administration. A qualified health care professional should be consulted before using any therapeutic product discussed. All readers and continuing education participants should verify all information and data before treating patients or employing any therapies described in this continuing education activity.

Faculty

Sarah Meade, BS
PharmD Candidate May 2023
UConn School of Pharmacy
Storrs, CT

Jeannette Y. Wick, RPh, MBA
Director, Office of Pharmacy Professional Development
UConn School of Pharmacy
Storrs, CT

 

Faculty Disclosure

In accordance with the Accreditation Council for Pharmacy Education (ACPE) Criteria for Quality and Interpretive Guidelines, The University of Connecticut School of Pharmacy requires that faculty disclose any relationship that the faculty may have with commercial entities whose products or services may be mentioned in the activity.

Jeannette Wick and Sarah Meade do not have any relationships with ineligible companies and therefore have nothing to disclose.

 

ABSTRACT

Americans may widely underestimate human trafficking’s current extent in the United States because of stereotypes about traffickers, victims, and sex workers, and also because many Americans lack knowledge about this topic. Despite the general public’s lack of knowledge, trafficking reports are rapidly increasing in the United States today. Healthcare for trafficking victims and survivors is often complicated due to clinicians’ lack of sensitivity about a patient’s trafficking experiences. Because victims of human trafficking are highly likely to seek medical care while under a trafficker’s control, training healthcare providers to identify, handle, and report suspected human trafficking is critical. Without trafficking education, providers’ biases and misunderstanding of victim trauma may hinder the ability to develop a trusting patient-provider relationship. Pharmacy teams should know how to identify human trafficking while protecting victims’ safely, providing appropriate resources for victims to seek help, and assisting with individualized treatment selection.

CONTENT

Content

Introduction

Human trafficking is a growing concern globally. Americans may widely underestimate human trafficking’s current extent in the United States (U.S.) because of stereotypes about traffickers, victims, and sex workers, and also because many Americans lack knowledge about this topic. Despite the general public’s lack of knowledge, trafficking reports are rapidly increasing in the United States today. The SIDEBAR defines terms associated with human trafficking.

 

SIDEBAR. Human Trafficking Definitions1,2

  • Human Trafficking: Recruitment, transfer, transportation, or receipt of people through force, manipulation, fraud, or threats to achieve control over a person for exploitation
  • Sex worker: A person who voluntarily provides sex work regularly or occasionally in commercial exchange for money or goods. Sex work differs from sexual exploitation, or the forcing of a person to commit sexual acts.
  • Survivors: people who have escaped their trafficking situations
  • Survivor-informed practice: Including meaningful input from a diverse community of survivors at all stages of a program or project, including development, implementation and evaluation
  • Traffickers: people using force, manipulation, threats, or fraud to force victims into exploitative situations
  • Trauma-informed care: collaborating with community resources to empower individuals to determine their own futures
  • Venue: The place in which trafficking occurs; human trafficking does not necessarily involve crossing state or international borders
  • Victims: people currently in an exploitative situation

 

In 2010, Faith Robles, a 14-year-old teenager from Mexico, moved in with her boyfriend’s family in Queens, New York.3 The family promised her a job that would “change her life,” but she did not learn this involved sleeping with men against her will—sometimes up to 30 men daily—until after her boyfriend smuggled her into the U.S. At the time, Robles was unaware that her boyfriend and four of his relatives were involved in a human trafficking ring. After she arrived, the family threatened to kill her family and traffic her sister if she sought help from authorities or did not comply with their demands. Robles was a victim of sex trafficking for three and a half years, suffering multiple beatings, sexual assaults, and a broken jaw following an escape attempt. She was finally able to escape at age 17 when she sought help from police officers.3 Hearing from survivors like Faith Robles has helped healthcare providers develop interventions that are survivor-informed. This continuing education activity will cover several aspects of human trafficking as it relates to pharmacy using evidence collected by reliable organizations and researchers.

 

Unfortunately, many victims in the U.S. today share stories like Robles’. In August 2022, the Federal Bureau of Investigation (FBI) announced that they located and identified 84 minors who were victims of sex trafficking during a nationwide sex trafficking operation. FBI agents found an additional 141 adult victims. Human trafficking rates continue to increase in the U.S. Reports of human trafficking to the National Center for Missing and Exploited Children Tipline increased from 21.7 million to 29.3 million reports from 2020 to 2021.4 Readers should note that collecting and reporting data on human trafficking has some limitations; many cases of human trafficking are never reported.5 Sometimes it’s because the victims are afraid or under a trafficker’s strict control and cannot seek help. Sometimes, it's because people who might be able to help a victim do not recognize the problem or have no idea how to help. Sometimes, it’s because systems have not looked at the issue, determined what (if anything) the system’s responsibilities are, and established policies and procedures to prevent trafficking and provide help.

 

Readers should also note that to be considered human trafficking, the trafficker need not move a victim across state or international borders; thinking that movement is a necessary component of human trafficking is a common misperception. Current federal laws only require that the trafficker has met the criteria for the 3 elements of “act,” “means,” and “purpose.”6

  • ACT means that the trafficker has recruited, transported, transferred, harbors, or received a victim
  • MEANS indicates the trafficker has used threat or use of force, coercion, fraud, deception, abuse of a position of vulnerability, payments or benefits, or abduction
  • PURPOSE is very simple; the trafficker’s sole purpose is to exploit the victim

In short, these requirements indicate that someone who coerces an individual to provide sex or labor against their will in exchange for housing or drugs would be considered a human trafficker, as doing so is exploitation. Someone who moves victims from place to place is also a trafficker, and in some states, people or organizations that knowingly harbor traffickers and their victims would also be complicit in human trafficking.7,8

 

In 2019, the National Human Trafficking Hotline reported California, Texas, and Florida as the top states for human trafficking with 1,507, 1,080, and 896 reported cases, respectively.9 Human trafficking often occurs along highways that provide access to easy getaways and quick transportation; many traffickers move their victims often to avoid detections. The busiest interstates in the U.S. include I-5 in the West, I-95 in the East, and I-80 stretching from California to New Jersey. The Polaris Project (see SIDEBAR) asserts that common trafficking venues include illicit massage parlors, informal underground businesses, and hotels and motels along major highways. For this reason, the National Association of Truck Stop Operators and large hotel chains, such as Marriott, offer training to help employees identify and report human trafficking victims.10

Pause and Ponder: How likely is your pharmacy to interact with victims or survivors of human trafficking? Why?

SIDEBAR. The Polaris Project

The Polaris Project is a nonprofit social justice organization that fights sex and labor trafficking through the U.S. National Human Trafficking Hotline. Polaris uses survivor-driven trafficking data to improve trafficking identification, provides assistance for victims and survivors, and educates the community. More information on the Polaris Project can be found on its website (https://polarisproject.org/).11

 

Polaris hosts the National Human Trafficking Hotline around the clock. Readers should make note of this resource, as it will often be the first and safest place to seek help when patients indicate or pharmacy staff suspects that an individual is being trafficked.

 

Human trafficking is a crime under federal and international law. The International Labor Organization estimates that the human trafficking “industry” generated $32 billion in 2005, making it the third largest source of income for organized crime.12,13 Current estimates are unavailable but would clearly be much larger. Human trafficking victims can come from any background and may live for years under their trafficker’s control. Victims may be trafficked by their own family, friends, or acquaintances with or without the victim’s knowledge.14,15

 

Human traffickers prey on others in reprehensible ways.16 Policy makers, public health groups, and researchers have tried to understand the motives behind human trafficking to identify factors that would help develop anti-trafficking interventions. Many publications indicate traffickers become involved primarily for financial gain because the profits associated with human trafficking can be enormous. Many of the interventions currently employed identify traffickers by tracking large quantities of cash and banking patterns. Recent research has found that in some cases, traffickers make considerably less money than expected. These traffickers may be motivated by cultural norms, ideology, or religions that devalue human life. Traffickers may be former victims who go on to recruit and control others. And some traffickers simply have sociopathic tendencies.16

 

Traffickers use various tactics to manipulate victims, including14

  • Debt-bondage
  • Emotional manipulation
  • Lies or deceit
  • Subjecting victims to unstable or unpredictable conditions
  • Physical, sexual, or psychological violence
  • Threats against family members
  • Transporting victims to unfamiliar places to create a language barrier
  • Withholding documents

 

Pre-trafficking vulnerabilities for victims include poverty, trauma, domestic violence, learning difficulties, lack of educational or work opportunities, loss of family, community- or gender-based violence, and natural disasters.2 Human trafficking survivors with vulnerabilities are at higher risk of re-victimization. The SIDEBAR describes types of human trafficking.

 

SIDEBAR. Types of Human Trafficking15,17,18

All forms of human trafficking include exploitation, abuse of vulnerable situations, psychological violence, and deprivation of freedom. Added physical and/or sexual violence is also common. Specific types of trafficking may include one or more of the following:

  • Sex trafficking: forcing someone to sell sex; more commonly affects women but often happens to children of both sexes
  • Forced labor: involuntary servitude, often in industries with large numbers of workers and little regulation; most common element of modern-day slavery
  • Domestic servitude: jobs related to domestic help; often hidden in plain sight
  • Debt bondage: begins with debt that the victim is unable to pay immediately; employer exploits the victim by adding additional expenses to increase debt
  • Other forms: forced marriage, organ removal for sale, and enforced crime

 

Readers should note that human trafficking differs from human smuggling. In human smuggling, the purported purpose is to transport or hide individuals who lack proper documentation (e.g., passports, driver’s licenses, or other identification) and circumvent officials without regard to immigration laws (a transportation-based crime). The people smuggled across borders often have chosen to be smuggled as a means to reach an otherwise inaccessible destination. Victims of human trafficking are generally held in circumstances against their will. Nevertheless, traffickers may also use victims’ immigration status and threaten to deport victims to coerce victims to do as they are told. In some cases, smuggling may lead to trafficking.

 

With 30% to 88% of U.S. trafficking victims seeking healthcare at least once during captivity, life-saving identification of trafficking victims in healthcare settings is crucial.19 Several researchers have attempted to estimate how many victims seek healthcare, but because of the nature of the topic and the risk associated with disclosure, it’s been difficult. Two studies shed some light on victims’ contact with healthcare providers. In a meta-analysis of 420 victims, 50% to 98% of victims reported seeking healthcare services in diverse medical settings while they were captive.20A second study found that roughly 63% of victims had visited emergency departments (ED) and identified hospitals and ED as their most frequent source of care.21 Trafficking victims tend to use complaint-based episodic acute care services (e.g., minute clinics, urgent care centers, and ED) more often than long-term comprehensive primary care services.22 Each visit represents an opportunity to identify potential behaviors, injuries, or actions that may signal victimization. Several studies have documented that healthcare professionals tend to have limited recognition and knowledge of human trafficking.23,24

 

No data is available about victims’ use of pharmacies, but pharmacy employees in community settings are likely to encounter human trafficking victims. Pharmacists and technicians should be prepared to recognize human trafficking signs for quick, appropriate, and life-saving action.

 

History of Human Trafficking in the United States

Let’s return to Faith Robles. Fortunately, Ms. Robles pressed charges against her boyfriend and his family for the damages and trauma she endured during captivity. In 2020, a judge sentenced Robles’ boyfriend and his family to prison terms of between 25 and 40 years under charges of “sex trafficking, sex trafficking conspiracy, sex trafficking of minors, interstate prostitution, alien smuggling, and money laundering conspiracy.”3 However, if Robles had reported her case in the early 1970s, she would not have been able to press charges; the federal government did not incorporate human trafficking crimes into U.S. law until recently.

 

The first U.S. law for human trafficking was the 1974 Child Abuse Prevention and Treatment Act (CAPTA). CAPTA required states to establish child abuse reporting laws as a condition of receiving federal funds.25 Mandated reporters and agencies to which people who observe or suspect abuse are to report vary by state law, but generally states require reporting in some capacity. Healthcare providers should always check their states’ applicable laws periodically so they know exactly what the state requires.

 

Mandated reporters are personnel who must report suspected or confirmed exploitation, abuse, or neglect of vulnerable populations. Alabama, Colorado, Connecticut, Hawaii, Oregon, Vermont, and Washington state laws specifically list pharmacists as mandated reporters for child victims. Other states list mandated reporters as “healthcare personnel” or people responsible for the care and/or treatment of child victims. Most states do not require mandatory reporting by healthcare personnel for victims 18 years old or older unless the adult is elderly or in some way vulnerable. States that do not require healthcare providers to report adult victims may do so because of the victims’ heightened safety risk, vulnerability, mistrust in authorities, and fear of their traffickers.26 Federal law does not currently require states to mandate reporting for adults or provide funding to meet reporting requirements.

 

The Trafficking Victims Protection Act (TVPA) of 2000 created the first comprehensive federal law to address human trafficking. The TVPA offered immigration relief for human trafficking victims, creation of public educational programs for prevention of future trafficking, and increased prosecution of trafficking.25,27 In January 2023, Congress reauthorized this Act. TVPA reauthorization added some additional coverage28:

  • It increases protections for child survivors of human trafficking
  • It provides funding for state welfare agencies to identify and assist child victims of human trafficking and work more closely and efficiently with the juvenile justice system
  • It eliminates barriers to services for child victims of human trafficking: consent from a parent or guardian is no longer necessary to apply for ID and other forms of identification, making it easier for children to apply for benefits and services
  • It expands support for research concerning social media’s impact on human trafficking

 

In 2013, the U.S. Department of Health and Human Services (HHS) created the Stop, Observe, Act, and Respond (SOAR) program to provide human trafficking training to healthcare and related professionals. The program includes victim identification and implementation of best practices for necessary reporting, referrals, communication, and treatment. In 2018, the HHS required public posting of best practices on the HHS website for entities receiving federal grants.29 SOAR’s program for individuals and groups are available at https://nhttac.acf.hhs.gov/soar/soar-for-individuals/soar-online.

 

In 2015, the Justice for Victims of Trafficking Act (JVTA) improved U.S. trafficking response. The law strengthened victim resources, including increasing individuals’ criminal liability if they buy commercial sex from victims, creation of the survivor-led U.S. Advisory Council on Human Trafficking, and a national strategy for combating human trafficking.30

 

Current human trafficking reporting laws are inconsistent due to variations among states; federal law does not clearly define a “mandated reporter” and does not require healthcare providers to report trafficking victims 18 years old or older.25 The American Hospital Association; the law firm of Jones Day; and the Health, Education, Advocacy, Linkage (HEAL) Trafficking network have collated state-specific reporting requirements for healthcare providers on the HEAL Trafficking website (https://healtrafficking.org/wp-content/uploads/2021/01/Human-Trafficking-and-Health-Care-Providers_Legal-Requirements-for-Reporting-and-Education-02_25_21.pdf).26

 

Pause and Ponder: What policies do you currently have in place to identify victims?

 

Healthcare Providers & Human Trafficking

Human trafficking victims are often in situations that compromise their health and safety. Most trafficked people seek healthcare from licensed providers at some point during their exploitation. Pharmacists and pharmacy technicians in outpatient settings may interact with victims without realizing their situation. Healthcare providers should be able to recognize possible victims and survivors confidently and take appropriate action to intervene if needed2; however, most health professionals report that they are unfamiliar with how to identify or respond to a trafficked person effectively.31

 

The Pharmacy Team in Action

Pharmacists’ involvement on the healthcare team is increasing and expanding from dispensing drugs to include medication and disease management and more expansive responsibilities. Pharmacy is unique because the available healthcare counseling is highly accessible by the public.

 

For safety and reporting, pharmacy team members should generally trust their instincts in a suspicious situation, especially when patients2,31,32

  • Act as if under control of another person, i.e., another person accompanies the patient, speaks for them, or there is a lack of rapport between the patient and accompanying individual
  • Report a history of frequent address changes, vagueness about where they live and/or medical history
  • Are present at a time when they should be in school
  • Have poor or concerning physical appearance suggesting captivity, neglect, and/or physical harm, i.e., poor hygiene or inappropriate clothing for current weather conditions or for their age (i.e., clothing is more promiscuous or revealing than normal for a teen)
  • Present with illnesses or injuries not easily explained, especially repeated or partially treated concerns
  • Exhibit signs and symptoms of self-harm, suicidal ideation, depression, or drug or alcohol misuse

 

Many state laws require pharmacists to counsel patients on new prescriptions. Prescription filling patterns that may signal trafficking include frequent sexually transmitted infection (STI) treatment, no insurance coverage, cash-only payments, prescriptions routinely lost or stolen, or a medical history of prescriptions from acute care clinics rather than a primary care physician.33 Victims may be hesitant to access healthcare because of safety concerns and are more likely to self-treat using over the counter (OTC) medications. Table 1 lists frequently used or misused OTC products for self-treatment, and this information may assist pharmacists and pharmacy technicians with screening for potential victims. Upon suspicion of trafficking, pharmacists should try to screen the patient privately.

 

Table 1. OTC Products Frequently Used or Misused for Self-Treatment of Trafficking-Associated Medical Concerns34,35

Health Concern OTC Products
Mental health and substance abuse St. John’s Wort

Dextromethorphan

Diphenhydramine

Pseudoephedrine

Phenylephrine

Sexual intercourse or urinary tract infection Condoms

Levonorgestrel (Plan B)

Miconazole

Pregnancy tests

Phenazopyridine

Genital anti-itch creams

Physical abuse Painkillers (i.e. acetaminophen, ibuprofen, aspirin)

First aid items (i.e., bandages, gauzes, antiseptics, Neosporin)

 

Privacy is essential to obtaining accurate and sensitive information that a victim might otherwise not be comfortable with sharing, especially for victims who fear for their safety and accompanied by an abuser. When pharmacy team members try to speak to the patient alone, they should remain calm and ask for privacy cautiously. The pharmacy team may emphasize the importance of privacy to the accompanying individual, perhaps by saying, “I’m going to step in here and speak to [patient’s name] alone because these are deeply personal health issues.” Note that this approach doesn’t ask a question—which might give the trafficker wiggle room to argue—but instead states a fact in a neutral manner. However, pharmacy staff should not push if they experience push-back from the suspected trafficker. Most pharmacies have a separate space for consultation or vaccinations that they may use when patients need privacy or to review sensitive information.

 

Pause and Ponder: What are some ways your pharmacy team can work to improve health outcomes for victims and survivors of human trafficking?

 

Avoiding Bias + Using the Correct Language

Pharmacy team members should be aware of their language when speaking to victims; personal biases may perpetuate stereotypes and influence clinical decision making for therapy or diagnoses.

 

Well-intentioned but poorly informed organizations or people can perpetuate stereotypes that are not evidence-based or all-encompassing. Understanding bias and perpetuated stereotypes reduces barriers to optimal healthcare. Stereotypes associated with trafficking including victim appearance, location, traffickers, or current situations prevent victims from escaping and/or receiving treatment.1 Table 2 addresses common stereotypes or myths associated with human trafficking in the United States. Pharmacy team members should question, acknowledge, and resolve their personal biases towards trafficking to reduce stigmatizing language and shame.

 

Table 2. Common Human Trafficking Myths vs Reality1,36

Myth Reality
Human trafficking victims are always undocumented foreign women or children. Victims can be any age, sex, ethnicity, or legal status. Sensationalized imagery of victims in the media, such as on TV or in the news, creates bias and provides an inconsistent narrative. Researchers estimate as many as half of all victims and survivors are male, but healthcare professionals are less likely to identify males as victims.
All commercial sex is human trafficking. Commercial sex is not human trafficking if the patient is an adult and gives informed consent for all activities involved.
Traffickers always hold victims against their will. Victims may stay involved in trafficking due to lack of resources to leave, fear for their safety, or manipulation by the trafficker. Victims may face shame from their trauma, including cultural attitudes about prostitution, debt, poor health conditions because of captivity, or working conditions.
Labor trafficking is only an issue in developing countries. Labor trafficking occurs in the U.S. but is reported less often than sex trafficking.
Human trafficking is always a violent crime. Human trafficking rarely includes physical force such as kidnapping. Most traffickers manipulate victims through psychological means such as defrauding, manipulating, or threatening vulnerable populations.
If individuals consented to be in their initial situation, they are not victims of trafficking. Initial consent to commercial sex or labor prior to force, manipulation, or fraud is irrelevant if the situation becomes one of coercion and exploitation later.

 

Healthcare providers should always use strength-based language to avoid victim blaming. For example, providers should refrain from using the term “child pornography,” and instead refer to it as “child sexual abuse materials.”1 For sex trafficking victims, they should refer to sexual acts during captivity as “exploitation” rather than “prostitution.”

Victims may experience intense shame surrounding their experiences that limits their ability to seek medical attention. Healthcare equity for trafficking victims starts with establishing trust. To gain trust, providers should identify and eliminate unconscious biases to improve service accessibility and health outcomes.

 

HEALTH CONSEQUENCES FOR VICTIMS

Traffickers often expose victims to numerous health risks before, during, and after exploitation and may restrict victims’ access to care. A key indicator of human trafficking is delayed care. Many patients have reasons to delay care (e.g., lack of insurance, no transportation, or difficult access to care), but delayed care in combination with other flags may indicate a patient is in trouble.37,38 Victims’ lack of access to proper care and poor environmental conditions may lead to deterioration or exacerbation of conditions.39

 

Mental Health and Addiction

Due to mental exhaustion from trauma, most victims face debilitating mental health issues. Victims may present with signs and symptoms of posttraumatic stress disorder (PTSD), depression, anxiety, dissociation, and substance use disorders. Serious symptoms warranting need for behavioral health therapy may include

  • Difficulty sleeping
  • Feeling detached or withdrawn
  • Guardedness
  • Hopelessness
  • Recurrent thoughts of trauma
  • Sudden emotional reaction when reminded of trauma
  • Suicidal ideation
  • Tendency to startle easily

 

Drug or alcohol addiction may exacerbate victim vulnerability, be used as a coping mechanism, or be a part of the trafficker’s tactic to keep victims hostage. An anti-trafficking service provider reported that 66% of victims claimed their substance use led to being trafficked, while 4.5% claimed their substance use began after being trafficked.40 Substance use throughout victimization occurred in 84.3% of victims, with the most common substances used being alcohol, marijuana, cocaine, and opioids.40 Due to high mortality rates from opioid overdoses, patients who are or have been trafficked warrant screening for opioid addictions.

 

Healthcare providers need to engage in trauma-informed care when helping victims of human trafficking.41 The experience of trauma overwhelms the victim’s ability to cope and healthcare providers need to recognize trauma’s impact on victims. They need to employ a trauma-informed approach. A trauma-informed approach has four components41:

  • Realizing trauma’s pervasive impact and the potential paths victims can follow for recovery
  • Recognizing trauma’s signs and symptoms in individuals, families, staff, and others involved in the system
  • Responding in a manner that fully integrates knowledge about trauma into policies, procedures, and practices
  • Taking care to communicate in ways that actively avoid retraumatization

 

A trauma-informed approach means collaborating with community resources to empower individuals to determine their own futures.41 Using the NHTRC hotline is a good way to initiate contact with community resources, as its staff is trained to help healthcare providers determine and identify the next best steps when trafficking is suspected or reported.

 

The Substance Abuse and Mental Health Services Administration (SAMHSA) supplies additional information on child trauma-informed care for patient and provider use (https://www.samhsa.gov/childrens-awareness-day/child-traumatic-stress-resources).40

 

Unprotected Sexual Intercourse

Victims of sex trafficking are at elevated risk for STIs and unwanted pregnancies. Pharmacists should attempt to counsel victims of sex trafficking on proper testing or screening, including the common signs and symptoms of various STIs, types of tests, and when and how to test. The CDC lists specific STI treatment guidelines on its website (https://www.cdc.gov/std/treatment-guidelines/default.htm).42

 

Monkeypox (now called Mpox) has been an emerging concern particularly for men who have sex with men. Monkeypox presents as a painful rash accompanied by fever, lethargy, muscle aches, and headaches.43 More information on monkeypox presentation, treatment and prevention can be found in UConn’s You Asked For It CE titled, “Go Bananas: Peel Away the Unknowns of Monkeypox.”

 

In female patients of childbearing age who have had recent unprotected sexual intercourse, pharmacists may recommend OTC emergency contraceptive pills (ECPs), or an intrauterine device (IUD) or “morning after” pill if allowed by state law.

 

Copper IUDs are a highly effective emergency contraceptive when inserted up to five days after sexual intercourse. This extended period for use and high efficacy rate may be beneficial for victims of human trafficking who may not have immediate access to emergency contraceptives, but IUD insertion can be expensive, and the trafficker may not allow the victim to see a qualified provider. The most common side effects for IUDs are heavy menstrual bleeding, spotty menstruation, or abdominal discomfort. Because victims of sex trafficking may have increased risk for STIs, victims should generally be tested and/or treated for STIs prior to IUD insertion and monitored after insertion.44

 

ECPs contain either levonorgestrel or ulipristal acetate (UPA) with 1.2% and 1.2-2.1% efficacy, respectively. UPA-containing ECPs are more effective between 72 and 120 hours post-intercourse than levonorgestrel-containing ECPs. Side effects may include nausea, vomiting, fatigue, and irregular vaginal bleeding.44

 

More information on emergency contraception eligibility criteria and safety is located on the World Health Organization’s (WHOs) website.44 In any emergency contraceptive, efficacy decreases as the time between intercourse and treatment increases. Pharmacists should inform patients that contraceptives do not induce abortions.

 

Physical Abuse

Victims may be vulnerable to physical abuse in captivity. Common signs of physical abuse are bruises, wounds, fractures, internal injuries, chronic pain, or head, neck and back injuries. Physical abuse may also present as substantial weight loss, dehydration, malnutrition, increased vulnerability to illness, and insomnia. Physical abuse is a medical emergency; if a patient’s safety is in danger, the pharmacy must report the situation to authorities immediately if the patient is a minor. States may require pharmacists to report abuse of an adult under state-specific mandatory reporting laws.

 

Acting on Human Trafficking

Upon suspicion or confirmation of trafficking, pharmacy technicians should alert the pharmacist and pharmacists should try to see the patient alone when possible. All involved staff must remain vigilant about everyone’s safety and avoid directly challenging the victim and/or accompanying individual. Direct confrontation, or raising the suspicion of an accompanying individual, can put a victim at risk of additional harm. It’s critical to note repeatedly that intervention can be dangerous. Most authorities indicate that the best action is to call the National Human Trafficking Hotline at 1(888) 3737-888 or call 911.38

 

In instances that involve language barriers, pharmacists should advise the accompanying individual that professional interpreters may be needed instead of relying on ad hoc interpreters (untrained children [who should only be used in emergencies], friends, family, or untrained staff).45-51 The reasons for working alongside interpreters (and interpreters prefer healthcare providers use the term “working alongside” rather than “using” to reflect that this is a collaborative endeavor) are evidence-based. Ad hoc interpreters are more likely to make mistakes, violate confidentiality rules, and increase risk of adverse outcomes. Professional interpreters are also fluid speakers and need not stop and think or reformulate language before translating. Untrained interpreters often leave out the niceties of language—niceties that increase trust and cultural understanding between patient and provider. When using an interpreter, the clinician should address the patient directly and seat the interpreter next to or slightly behind the patient. 45-51 Readers who want to learn more about the nuances of professional interpretation may be interested in What’s in a Word? A Guide to Understanding Interpreting and Translation, available online for free at https://www.ncihc.org/assets/documents/publications/Whats_in_a_Word_Guide.pdf.

 

Pharmacists and technicians should be patient, compassionate, and sensitive to build trust and gather sufficient information. Since 2011, the Institute of Medicine and the U.S. Department of Health and Human Services have recommended screening for intimate partner violence and abuse by asking patients, “Do you feel safe at home?” at each visit.52 In 2013, the U.S. Preventive Services Task Force also made this recommendation. Although the question was meant to identify intimate partner violence, it has identified other types of abuse. This question surprises many patients, and many healthcare practitioners find it uncomfortable to ask. Pharmacy staff might ask this question, but it probably should not be the first question to the suspected victim. Saving this and similar questions should come after establishing some rapport with the patient and the patient seems comfortable. Regardless, patients may not answer truthfully or at all, but just asking the question let’s victims know that someone cares, and help is available.52 When interviewing patients, pharmacists should ask “trauma-informed” questions but consider the harmful effect of reliving traumatic experiences.2 Table 3 provides additional appropriate example questions when screening patients for human trafficking.

 

Table 3. Example Screening Tool for Suspicion of Human Trafficking2,14,17

  • Are you limited as to who you can talk to and when?
  • Do you have the freedom to leave your current job?
  • Do you have to ask permission for necessities, such as eating or using the bathroom?
  • Do you owe your employer money or other debts?
  • Has anyone ever physically hit, threatened, or raped you or anyone you work with for any reason?
  • Has anyone ever forced you into sexual intercourse for work?
  • Has anyone threatened your family?
  • Has anyone threatened you with deportation?
  • Is someone else controlling your money or finances?
  • Is someone else in control of where you are allowed to go?
  • Is someone else in control of your identification documents, including your birth certificate or passports?
  • Was someone else in control of your travel arrangements to the U.S.?
  • What is your working or living condition like?

 

Healthcare providers may be unable to help patients involved in human trafficking—affected individuals may be too afraid to engage. Individuals need to be able and willing to help themselves. Providers should also offer patients choices; if the patient does not verbalize immediate danger, pharmacists can gently discuss reporting to police, non-government organizations, or helplines. When patients do not want to act, healthcare providers should prioritize care for the patient’s health conditions, gain the victim’s trust, and document clearly. Pharmacy teams should write down any information that may be helpful in an investigation, including time of day, address, and vehicle information, if available.

 

Providers must always consider security risks. Pharmacy staff should never attempt to confront a potential human trafficker or victim directly. They should try to arrange follow-up with patients and document their contact information. Pharmacists may also ask for consent to call the patient’s primary care provider.

 

That said, pharmacy teams need to follow statutory and healthcare organization procedures at all times. Again, the National Human Trafficking Resource Center (NHTRC) hotline is available for pharmacy teams to use and pharmacy personnel can call the hotline for guidance. The NHTRC helps providers identify local resources and coordinate with social service organizations. It’s hotline is available 24/7 at 1 (888) 3737-888 or text HELP or INFO to “BeFree” (233733). Pharmacists may choose to submit an anonymous tip online on the NHTRC website (https://humantraffickinghotline.org/report-trafficking).33 If the patient is a minor or in imminent danger, a staff member should stay with the patient, remain calm, and contact 911 or the local police department when it is safe to do so.

 

Providers should do their best to ensure proper self-care after a stressful or intense situation.

 

Conclusion

Faith Robles is now a spokeswoman, advocate, and aftercare provider for victims of human trafficking which demonstrates that victims, when they can access help, can survive and flourish.53 Pharmacy teams should remain vigilant when encountering suspicious circumstances. Trafficking victims may have multiple health issues because of their trauma and abuse. Pharmacy team members can easily recognize signs of human trafficking through prescription, disease, or behavioral patterns. Individualized screening and determination of the type of trafficking involved is necessary for treatment recommendations and referrals. Pharmacy teams should address victims’ concerns while considering the patient’s health, safety, and personal hardships. Pharmacies may advocate for federal and/or local legislation focused on trafficking prevention and education to drive large-scale change.

Pharmacist Post Test (for viewing only)

PHARMACIST POSTTEST

Learner Questions for Pharmacists
Learning Objectives
At the end of this continuing education activity, pharmacists will be able to
• Review the history and current laws of human trafficking in the United States
• Recognize common terms, warning signs, and/or vulnerabilities for human trafficking in pharmacy patients/customers
• Describe pharmacists’ impact on identifying and supporting victims and survivors of human trafficking
• Ensure proper referral, treatment, and counseling for common health risks associated with human trafficking

1. Which of the following statements describes the Trafficking Victims Protection Act (TVPA) of 2000?
a. TVPA was the first law to address child trafficking reporting laws
b. TVPA offers immigration relief for victims and survivors of human trafficking
c. TVPA created the US Advisory Council on Human Trafficking

2. Which of the following is a federal law and a state-specific law that addresses healthcare providers’ responsibilities regarding human trafficking?
a. Reporting of human trafficking victims 17 years old or younger
b. Specific definitions of “mandated reporters”
c. Mandated human trafficking training for healthcare workers

3. Which act included increased individuals’ criminal liability if they buy commercial sex from victims?
a. The Child Abuse Prevention and Treatment Act (CAPTA)
b. The Stop, Observe, Act, and Respond (SOAR) to Health and Wellness Act
c. The Justice for Victims of Trafficking Act (JVTA)

4. Which action may result in increased harm for human trafficking victims when accompanied by an individual?
a. Asking to see the patient alone during private exams because your state requires prescription counseling
b. Allowing the accompanied individual to act as an interpreter when there is a language barrier
c. Staying aware of your own safety when encountering a victim and accompanying individual
5. Which of the following situations during counseling may suggest a patient may be a victim of human trafficking?
a. A 37-year-old female patient approaches the consulting window alone asking to pick up her birth control prescription 2 days earlier than allowed by insurance
b. A patient calls the pharmacy asking about selection of vaginal itch creams and pregnancy tests three separate times within one month
c. A smiling 9-year-old patient accompanied by his legal guardian picking up a new prescription for an albuterol inhaler for the child

6. When heightening awareness of human trafficking, what do healthcare providers need to know?
a. Human trafficking victims are likely to seek healthcare at least once during captivity
b. Human trafficking victims are predominately female adults aged 25 to 34
c. Traffickers often force victims into trafficking through physical force such as kidnapping

7. A young woman visits the pharmacy accompanied by a man who seems to hover and intervene in your conversations with the woman. You are able to gently pry her away and interview her in the counseling room. She tearfully says that 4 days ago she had unprotected sexual intercourse with a man who told her he may have an STI after they had sex. Which emergency contraceptive would you choose for her?
a. Ulipristal acetate (UPA) emergency contraceptive pills
b. Levonorgestrel emergency contraceptive pills
c. Refer her for a copper intrauterine device

8. A young male who is unkempt and has a prescription for an antibiotic used to treat syphilis listens intently as you counsel him on how to take the medication. You ask him how he has been feeling in general in an attempt to build trust. He says that his clothes have gotten tight, has missed school because he sleeps heavily all night and oversleeps often, and he periodically experiences headache, fatigue, dizziness and thirst. Which symptom set may indicate he may be a victim of human trafficking?
a. His clothes have gotten tight
b. Oversleeping
c. Headache, fatigue, dizziness and thirst

9. Alex, Ben, and Carrie each describe symptoms that seem to suggest opioid addictions. Alex, 17, says that he has used heroin since he was 12. Ben, 42, says that he currently has little access to opioids and needs treatment to reduce craving. Carrie, 15, says that she uses alcohol when her “friend” cannot find opioids for her. Which patients are most in need of screening for possible human trafficking?
a. Alex and Ben
b. Ben and Carrie
c. Carrie and Alex

10. The lead technician comes to you and says that she tried to complete medication reconciliation for a young woman. She is 16 years old and has just been admitted to the emergency department for abdominal pain that started with a diagnosis of chlamydia two weeks ago. Now, she may have pelvic inflammatory disease. The patient does not speak English. The woman’s companion said that he would translate for her because she has antisocial personality disorder. Choose the BEST way to approach this dilemma.
a. Say, “Are you aware that your actions seems suspicious? Either let us talk to her in private or we are going to call the police”
b. Say, “We have called a translator, and we’ll speak to [patient’s name] alone because these are deeply personal health issues.”
c. Say, “You have a choice here. We can use the hospital translator with or without you present, and you can take your friend and leave AMA.”

Pharmacy Technician Post Test (for viewing only)

Learner Questions for Pharmacy Technicians
At the end of this continuing education activity, the pharmacy technician will be able to
• Review the history and current laws of human trafficking in the United States
• Recognize common terms, warning signs, and/or vulnerabilities for human trafficking in the pharmacy
• Identify signs/signals of human trafficking red flags to notify pharmacists or law enforcement

1. Which of the following statements describes the Trafficking Victims Protection Act (TVPA) of 2000?
a. TVPA was the first law to address child trafficking reporting laws
b. TVPA offers immigration relief for victims and survivors of human trafficking
c. TVPA created the US Advisory Council on Human Trafficking

2. Which of the following is a federal law and a state-specific law that addresses healthcare providers’ responsibilities regarding human trafficking?
a. Reporting of human trafficking victims 17 years old or younger
b. Specific definitions of “mandated reporters”
c. Mandated human trafficking training for healthcare workers

3. Which act included increased individuals’ criminal liability if they buy commercial sex from victims?
a. The Child Abuse Prevention and Treatment Act (CAPTA)
b. The Stop, Observe, Act, and Respond (SOAR) to Health and Wellness Act
c. The Justice for Victims of Trafficking Act (JVTA)

4. Which of the following is a pre-trafficking vulnerability for victims?
a. Natural disasters
b. High insurance copays
c. Well-paying occupation

5. Which of the following types of trafficking matches its definition below?
a. Forced Labor: involuntary servitude, often from industries with large numbers of workers and little regulation
b. Domestic servitude: begins with debt that cannot be paid immediately; employer exploits the victim by adding additional expenses to increase debt
c. Debt bondage: forcing someone to sell sex
6. Which of the following OTC products are human trafficking victims most likely to use or misuse?
a. Esomeprazole (Nexium)
b. Oxymetazoline (Sinex)
c. Acetaminophen (Tylenol)

7. Which statement below is a common myth regarding human trafficking in the United States?
a. Labor trafficking exists in the United States, but public health officials less often report labor trafficking compared to sex trafficking
b. All commercial sex is human trafficking
c. Human trafficking rarely uses physical force such as kidnapping

8. Select the patient interaction that should prompt you to inform your pharmacist of potential human trafficking.
a. A young adult patient who hands you a handwritten list of their prescriptions and medical history
b. An adolescent whose breath smells of alcohol and is dressed in shorts and a tank top for 10⁰F weather in January
c. A female patient asking to fill her birth control 2 days earlier than her insurance will cover because she’s going on vacation to Miami tomorrow
9. Three patients confirm that they are human trafficking victims but state that they are not in imminent danger and ask you not to contact authorities. You MUST contact the authorities for one patient under federal law. Which one is it?
a. An 18-year-old patient who has not showered in 3 weeks
b. An 11-year-old patient accompanied by her father
c. A 23-year-old patient taking medications for his anxiety disorder
10. Upon suspicion of human trafficking, which of the following is an appropriate intervention for pharmacy technicians?
a. Directly confront the individual accompanying the victim and tell them to stay where they are while you get the pharmacist
b. When alone with the patient, start a discussion with in-depth questions about their trauma for a more detailed background
c. Prioritize everyone’s safety, inform the pharmacy team of the situation, and call the authorities when appropriate

References

Full List of References

REFERENCES

    References

     

    1. Jessica L. Peck, Jordan Greenbaum & Hanni Stoklosa (2021): Mandated Continuing Education Requirements for Health Care Professional State Licensure: The Texas Model, Journal of Human Trafficking, DOI: 10.1080/23322705.2021.1981708 [Epub ahead of print]
    2. Hunt J, Witkin R, Katona C. Identifying human trafficking in adults. BMJ. 2020; 371 doi:10.1136/bmj.m4683 [Epub ahead of print]
    3. Rasmussen A. 'I Will Never Forgive You': Sex Trafficking Survivor Helps Put Her Captors Behind Bars. CrimeFeed. Published July 2022. Accessed January 5, 2023. https://www.investigationdiscovery.com/crimefeed/id-shows/on-tv0/in-pursuit-with-john-walsh/articles/raymond-dean-holley-easter-sunday-child-sex-abuse-fugitive
    4. Chen S. FBI locates 121 minors, 141 adults in nationwide human trafficking bust. Axios. Published August 15, 2022. Accessed January 5, 2023. https://www.axios.com/2022/08/15/fbi-human-trafficking-operation-recovery
    5. Gaps in Reporting Human trafficking incidents result in significant undercounting. National Institute of Justice. August 4, 2020. Accessed January 5, 2023. https://nij.ojp.gov/topics/articles/gaps-reporting-human-trafficking-incidents-result-significant-undercounting
    6. The Trafficking Victims Protection Act of 2000. U.S. Department of Health & Human Services, Office on Tafficking in Persons. Accessed January 5, 20232. https://www.acf.hhs.gov/archive/otip/policy-guidance/state-letter-01-13
    7. Van Steenwyk J. Human trafficking: What landlords & property managers must know. All Property Management web site. Accessed January 5, 2023. https://www.allpropertymanagement.com/blog/post/human-trafficking-facts-for-landlords/
    8. Landlords Coercing Tenants Unable to Pay Rent to Provide Sex: Sex Trafficking or Not? Polaris web site. Accessed January 5, 2023. https://polarisproject.org/blog/2020/05/landlords-coercing-tenants-unable-to-pay-rent-to-provide-sex-sex-trafficking-or-not/
    9. Where does human trafficking happen? DeliverFund. Published June 9, 2022. Accessed January 5, 2023. https://deliverfund.org/the-human-trafficking-problem-in-america/where-does-human-trafficking-happen/
    10. Datta M. Sex trafficking in the US: Four questions answered. Phys.org. Published March 8, 2019. Accessed January 5, 2023. https://phys.org/news/2019-03-sex-trafficking.html
    11. The Polaris Project. About Us. Accessed January 5, 2023. https://polarisproject.org/about-us/.
    12. Dovydaitis T. Human trafficking: the role of the health care provider. J Midwifery Womens Health. 2010;55(5):462-467.
    13. Feingold D. Human trafficking. Foreign Policy. 2005; 150:26-30.
    14. Zimmerman C, Borland R. Caring for Trafficked Persons: Guidance for Health Providers. International Organization for Migration. 2009. Accessed January 5, 2023. https://www.iom.int/caring-trafficked-persons-guide-health-providers
    15. Polaris. Human Trafficking Trends in 2020 An analysis of data from the U.S. National Human Trafficking Hotline. Accessed January 5, 2023. https://polarisproject.org/wp-content/uploads/2022/01/Human-Trafficking-Trends-in-2020-by-Polaris.pdf
    16. Clark MC. Questioning the Notion of Financial Gain as the Primary Motivation of Human Traffickers. Anti-Trafficking Rev. 2022;18:180-184.
    17. Leslie J. Human trafficking: Clinical assessment guideline. J Trauma Nursing. 2018;25(5):282-289.
    18. Human trafficking vs human smuggling. US Immigration and Customs Enforcement. Published Summer 2017. Accessed January 5, 2023. www.ice.gov/sites/default/files/documents/Report/2017/CSReport-13-1.pdf
    19. Stoklosa H, Showalter E, Melnick A, Rothman EF. Health Care Providers’ experience with a protocol for the identification, treatment, and referral of human-trafficking victims. J Human Trafficking. 2016;3(3):182-192.
    20. Armstrong S, Greenbaum VJ. Using Survivors' Voices to Guide the Identification and Care of Trafficked Persons by U.S. Health Care Professionals: A Systematic Review. Adv Emerg Nurs J. 2019;41(3):244-260. doi:10.1097/TME.0000000000000257
    21. Lederer LJ, Wetzel CA. The health consequences of sex trafficking and their implications for identifying victims in healthcare facilities. Ann Health Law. 2014;23(1);61-87.
    22. Wallace C, Lavina I, Mollen C. Share our stories: An exploration of the healthcare experiences of child sex trafficking survivors. Child Abuse Negl. 2021;112:104896. doi:10.1016/j.chiabu.2020.104896
    23. McAmis NE, Mirabella AC, McCarthy EM, et al. Assessing healthcare provider knowledge of human trafficking. PLoS One. 2022;17(3):e0264338. doi: 10.1371/journal.pone.0264338
    24. Recknor FH, Gemeinhardt G, Selwyn BJ. Health care provider challenges to the identification of human trafficking in health care settings: a qualitative study. J Human Trafficking. 2018;4(3):1-18. doi: 10.1080/23322705.2017.1348740
    25. Jones Day White Paper. Human Trafficking and Health Care Providers: Legal Requirements for Reporting and Education. Published August 2020. Accessed January 5, 2023. https://healtrafficking.org/wp-content/uploads/2021/01/Human-Trafficking-and-Health-Care-Providers_Legal-Requirements-for-Reporting-and-Education-02_25_21.pdf.
    26. Kirschner F, Godspeed T, Baker C, Lynch S, Jones H. Human trafficking and Health Care Providers: Legal Requirements for Reporting and Education. HEAL Trafficking: Health, Education, Advocacy, Linkage. Accessed January 5, 2023. https://healtrafficking.org/2021/01/legal-requirements-for-reporting-and-education/
    27. Federal law. National Human Trafficking Hotline. Accessed January 5, 2023. https://humantraffickinghotline.org/what-human-trafficking/federal-law.
    28. Delgado A. The trafficking victims protection act is signed into law. January 9, 2023. Accessed February 17, 2023. https://www.ecpatusa.org/blog/2023/1/4/trafficking-victims-protection-act-signed-into-law
    29. The SOAR to Health and Wellness Act of 2018, Pub L. No. 115-398 § 132 Stat. 5329 (2018).
    30. Human trafficking laws & regulations. US Department of Homeland Security. Accessed January 5, 2023. https://www.dhs.gov/human-trafficking-laws-regulations.
    31. Nordstrom B. Multidisciplinary Human Trafficking Education: Inpatient and Outpatient Healthcare Settings. J Human Trafficking. 2020;8(2):184-194
    32. Indicators of Human Trafficking. Homeland Security Blue Campaign. Accessed January 5, 2023. https://www.dhs.gov/blue-campaign/indicators-human-trafficking
    33. Palombi L, Ochten H, Patz C. The Pharmacists’ Role in Identifying and Supporting Victims of Human Trafficking. Human Trafficking. 2019;5(3):255-266.
    34. Terrie Y. Promote the Safe and Proper Use of OTC Drugs . Pharmacy Times . 2019;85(4).
    35. Trygstad T, DiMaggio T, Ogurchak J, Arakelians S, Gallagher A, James D. 2022 Survey of Pharmacists' OTC Recommendations. OTC Guide. (2022):3-60. Accessed January 5, 2023. https://cdn.sanity.io/files/0vv8moc6/pharmacytimes/86326ebdabcad93c75193a50a94fb30cf4e10661.pdf/2022OTCGuide_EditorialPagesOnly-R1%20(2).pdf
    36. Myths & Facts. National Human Trafficking Hotline. Published May 3, 2019.Accessed January 5, 2023. https://humantraffickinghotline.org/what-human-trafficking/myths-misconceptions
    37. Baldwin SB, Eisenman DP, Sayles JN, Ryan G, Chuang KS. Identification of human trafficking victims in health care settings. Health Hum Rights. 2011;13(1):E36-E49.
    38. Schuette, B., (2015). Michigan attorney general. Human trafficking “Red Flags” for health care professionals. Accessed December 5, 2022. https://www.michigan.gov/ag/-/media/Project/Websites/AG/human-trafficking/Updated-Red-Flags-for-Responders/Red_Flags_-_Health_Care_598573_7.pdf?rev=827954e5cf9647ca9fc9369046759735
    39. Stoklosa H, MacGibbon M, Stoklosa J. Human trafficking, mental illness, and addiction: Avoiding diagnostic overshadowing. AMA Journal of Ethics. 2017;19(1):23-34.
    40. Resources for Child Trauma-Informed Care. Substance Abuse and Mental Health Services Administration. Accessed January 5, 2023. https://www.samhsa.gov/childrens-awareness-day/child-traumatic-stress-resources
    41. Zarnello L. Implementing trauma-informed care across the lifespan to acknowledge childhood adverse event prevalence: best clinical practices. Nurse Pract. 2023;48(2):14-21. doi:10.1097/01.NPR.0000000000000002
    42. Workowski K, Bachmann L, Chan P, et.al. STI treatment guidelines. Centers for Disease Control and Prevention. Published July 22, 2021. Accessed January 5, 2023. https://www.cdc.gov/std/treatment-guidelines/default.htm
    43. MPox. Ceneters for Disease Control and Prevention. Accessed January 5, 2023. https://www.cdc.gov/poxvirus/monkeypox/index.html
    44. World Health Organization. Emergency contraception. Published November 9, 2021. Accessed January 5, 2023. https://www.who.int/news-room/fact-sheets/detail/emergency-contraception
    45. Juckett G, Unger K. Appropriate use of medical interpreters. Am Fam Physician. 2014;90(7):476-480.
    46. Karliner LS, Jacobs EA, Chen AH, Mutha S. Do professional interpreters improve clinical care for patients with limited English proficiency? A systematic review of the literature. Health Serv Res. 2007;42:727-754.
    47. Flores G, Laws MB, Mayo SJ, et al. Errors in medical interpretation and their potential clinical consequences in pediatric encounters. Pediatrics. 2003;111:6-14.
    48. Jacobs EA, Lauderdale DS, Meltzer D, Shorey JM, Levinson W, Thisted RA. Impact of interpreter services on delivery of health care to limited-English-proficient patients. J Gen Intern Med. 2001;16:468-474.
    49. What's in a Word? A Guide to Understanding Interpreting and Translation in Healthcare. Los Angeles, CA: National Health Law Program; 2010. Accessed January 5, 2023. https://www.ncihc.org/assets/documents/publications/Whats_in_a_Word_Guide.pdf
    50. Jackson JC, Nguyen D, Hu N, Harris R, Terasaki GS. Alterations in medical interpretation during routine primary care. J Gen Intern Med. 2011;26:259-264.
    51. Nápoles A, Santoyo-Olsson J, Karliner L, Gregorich SE, Pérez-Stable EJ. Inaccurate language interpretation and its clinical significance in the medical encounters of Spanish-speaking Latinos. Med Care. 2015;53:940-947.
    52. Scott M. Doctors asking about domestic violence is important, but daunting. December 16, 2015. Accessed February 7, 2023. https://whyy.org/segments/doctors-asking-about-domestic-violence-is-important-but-daunting/
    53. Dahlia's Hope. Accessed January 5, 2023. https://www.dahliashope.org/

     

    HIV Pre- and Post-Exposure Prophylaxis in Adolescents and Young Adults

    Learning Objectives

     

    After completing this application-based continuing education activity, pharmacists will be able to

    • Discuss the prevalence of HIV/AIDS in humans and associated stigma in the adolescent and young adult population
    • Identify risk factors for HIV infection in adolescent and young adults
    • Review pre-/post-exposure prophylaxis methods for HIV prevention in the adolescent/young adult population
    • Maximize the pharmacists’ role in HIV prevention in the adolescent/young adult population

    After completing this application-based continuing education activity, pharmacy technicians will be able to

    • Recall the prevalence of HIV/AIDS in humans and associated stigma in the adolescent and young adult population
    • List high-risk activities for HIV exposure
    • Describe available patient assistance programs & cost assistance programs for pre- and post-exposure HIV prophylaxis
    • Identify antiretrovirals used for pre-/post-exposure HIV prophylaxis in the adolescent and young adult population

    Image showing tablets with 'PrEP' inscribed upon them.

     

    Release Date: February 15, 2023

    Expiration Date: February 15, 2026

    Course Fee

    FREE

    There is no grant funding for this CE activity

    ACPE UANs

    Pharmacist: 0009-0000-23-004-H02-P

    Pharmacy Technician: 0009-0000-23-004-H02-T

    Session Codes

    Pharmacist:  23YC04-ABC34

    Pharmacy Technician:  23YC04-CBA43

    Accreditation Hours

    1.5 hours of CE

    Accreditation Statements

    The University of Connecticut School of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.  Statements of credit for the online activity ACPE UAN 0009-0000-23-004-H02-P/T  will be awarded when the post test and evaluation have been completed and passed with a 70% or better. Your CE credits will be uploaded to your CPE monitor profile within 2 weeks of completion of the program.

     

    Disclosure of Discussions of Off-label and Investigational Drug Use

    The material presented here does not necessarily reflect the views of The University of Connecticut School of Pharmacy or its co-sponsor affiliates. These materials may discuss uses and dosages for therapeutic products, processes, procedures and inferred diagnoses that have not been approved by the United States Food and Drug Administration. A qualified health care professional should be consulted before using any therapeutic product discussed. All readers and continuing education participants should verify all information and data before treating patients or employing any therapies described in this continuing education activity.

    Faculty

    Mikayla Arriaga,
    PharmD Candidate May 2023
    UConn School of Pharmacy
    Storrs, CT

    Saba Azam
    PharmD Candidate May 2023
    UConn School of Pharmacy
    Storrs, CT

    Daniela Barisano
    PharmD Candidate May 2023
    UConn School of Pharmacy
    Storrs, CT

    Jennifer Girotto, PharmD, BCPPS, BCIDP
    Assistant Professor and Assistant Department Head
    UConn School of Pharmacy
    Storrs, CT

    Ying Han, PharmD
    Staff Pharmacist CVS
    Cheshire, CT

    Diana Levytska
    PharmD Candidate May 2023
    UConn School of Pharmacy
    Storrs, CT

     

     

    Faculty Disclosure

    In accordance with the Accreditation Council for Pharmacy Education (ACPE) Criteria for Quality and Interpretive Guidelines, The University of Connecticut School of Pharmacy requires that faculty disclose any relationship that the faculty may have with commercial entities whose products or services may be mentioned in the activity.

    Drs. Han and Girotto, and Ms. Azam, Arriaga, Barisano, and Levytska do not have any relationships with ineligible companies and therefore have nothing to disclose.

     

    ABSTRACT

    Human immunodeficiency virus (HIV) attacks the body’s immune system by destroying white blood cells (WBCs). When uncontrolled, destruction of WBCs makes patients more susceptible to opportunistic infections throughout the body. Adolescents and young adults aged 13 to 24 years are among one of the largest groups at risk for acquiring HIV, accounting for a fifth of new HIV infections. Risk factors for HIV infection include unsafe sexual practices and injection drug-use. Patients can employ many preventive strategies to decrease risk of acquiring HIV infection. These include using condoms during sex, avoiding needle sharing, and taking prophylactic antiretrovirals. Using an antiretroviral effective against HIV routinely before exposure—referred to as pre-exposure prophylaxis (PrEP)—reduces the likelihood of acquiring HIV. Providers prescribe PrEP to patients who are not infected with HIV who engage in high-risk activities. Post-exposure prophylaxis (PEP) differs from PrEP in that patients take antiretrovirals within 72 hours after a possible HIV exposure (i.e., through blood contact or sexual activity). It is important that healthcare providers counsel and educate young patients about PEP and PrEP to prevent them from becoming infected with HIV. Living with HIV remains highly stigmatized. Recognizing and actively addressing stigma through healthcare team interventions is critical to ensure the well-being of affected patients.

    CONTENT

    Content

    INTRODUCTION

    Human immunodeficiency virus (HIV) attacks the body’s immune system by destroying CD4 helper T cells. These cells are required for adaptive immunity (acquired immunity that adapts to real-time pathogen exposure), as they stimulate key players in the unimpaired immune response. Once patients are infected with HIV, starting potent combination antiretroviral therapy immediately can decrease morbidity and extend life. If the virus remains unchecked and progresses, patients develop high viral loads (the amount of virus in an infected person’s blood expressed as the number of viral particles/mL of blood) and slowly deplete their CD4 helper T cells, elevating risk for opportunistic infections (e.g., pneumocystis pneumonia, bacterial infections such as pneumococcal disease, disseminated mycobacterium avium infections).1

     

    While HIV remains a persistent problem in the United States (U.S.) across all age groups, young people are disproportionately affected. A 2018 report stated 15,820 adults and adolescents diagnosed with HIV died in the U.S. and its six dependent areas.2 Several groups have tracked HIV infections in youths and presented startling statistics. According to the Centers for Disease Control and Prevention (CDC), individuals aged 13 to 24 years accounted for 21% of all new HIV diagnoses in 2018.2 Even more concerning, experts estimate that more than 40% of HIV-infected youth are undiagnosed.3 Although public health officials and healthcare systems have made efforts to improve access to care, recent data suggests that effective HIV prevention and treatment are not reaching those who could most benefit from them (e.g., men who have sex with men [MSM], transgender persons, Black and Hispanic/Latinx people).4

     

    HIV infection is most likely to occur through male-to-male sexual contact (81%), heterosexual contact (10%), and injection drug use (5%).5 Data from the Youth Risk Behavior Survey shows that high school students engage in behaviors that increase risk of acquiring HIV5:

    • Low rates of condom use: 45.7% report not using a condom during their last sexual encounter
    • Low perception of risk: 90.6% of sexually active students report never being tested for HIV
    • Substance use/abuse and sex: 21.2% report drinking alcohol or using drugs before last sexual intercourse
    • Multiple sexual partners: 8.6% report sexual intercourse with four or more partners
    • High rates of sexually transmitted infections (STIs): about half of all reported STIs are in those aged 15 to 24 years

     

    Sexual exploration is a normal part of adolescent development and sexual activity can be both unplanned and unwanted. In 2011-2013, 47% and 44% of 15- to 19-year-old males and females, respectively, had engaged in sexual intercourse.6 The onset of sexual activity during adolescence coupled with a propensity for substance use experimentation and low rates of condom use increase adolescents’ vulnerability to infection with HIV and other STIs.5 Therefore, sexual education including material on HIV and acquired immunodeficiency syndrome (AIDS) is crucial to prevent HIV infection among adolescents and young adults.

     

    HIV’s greater risk and prevalence in adolescents requires focused clinical attention. Early HIV diagnosis and treatment in adolescence and young adulthood reduces risk for HIV transmission and increases the likelihood of a functional lifestyle similar to that of non-infected individuals. There are many HIV prevention methods, including

    • pre-exposure prophylaxis (PrEP) and post-exposure prophylaxis (PEP) to prevent HIV infection
    • avoiding risky behaviors that can result in HIV exposure/infection
    • testing and treatment to reduce mother-to-child HIV transmission

     

    National U.S. data shows that from 2012 to 2018, among commercially insured individuals at high risk for HIV/AIDS, 13% of patients aged older than 35, 9.6% of individuals aged 25 to 34, but only 2.7% of patients aged 16 to 24 had received PrEP. 2 The low prescribing rate among youths may be related to healthcare providers’ lack of knowledge about PrEP or discomfort with prescribing PrEP.2 Thus, healthcare providers who care for adolescents and young adults need education on discussing sexual health with pointed discussion about STI and HIV prevention and recommending or prescribing PrEP when appropriate.5

     

    PRE-EXPOSURE PROPHYLAXIS

    Taking antiviral medications to reduce the risk of acquiring HIV in the event of exposure is referred to as PrEP. Studies have shown PrEP is highly effective when used consistently (i.e., taken as directed) before HIV exposure during sex or injection drug use.7,8 Specifically, the CDC indicates PrEP can reduce the risk of contracting HIV from sex by about 99% and from injecting drugs by 74% to 84%.7

     

    The most updated “Preexposure Prophylaxis for the Prevention of HIV Infection in the U.S.” clinical practice guidelines state that clinicians should offer PrEP to adolescents who weigh more than 35 kg (77 lbs) who fit the following criteria9:

    • HIV negative, but participate in sexual behaviors that put them at risk for HIV infection (e.g., recent STI, sex with an HIV-positive partner, inconsistent condom use)
    • HIV negative, but inject drugs

     

    The guidelines also define clinical eligibility by the potential medication regimen9:

    • All PrEP regimens (oral and injectable)
      • Negative HIV test result within the last 7 days
      • No signs/symptoms of acute HIV infection
      • No contraindicated medications or conditions
    • Oral daily regimens only (not injectable cabotegravir)
      • Negative hepatitis B virus infection
      • Adequate renal function (discussed below)

     

    PAUSE & PONDER:  How can you identify patients in your practice who may benefit from PrEP?

     

    Oral PrEP Regimens

    Two emtricitabine-based oral regimens are U.S. Food and Drug Administration (FDA) approved for HIV PrEP. The first to be approved was emtricitabine/tenofovir disoproxil fumarate (DF; brand name Truvada) in 2012.10 The FDA expanded the indication for HIV PrEP to at-risk adolescents (age 12 years and older) and adults weighing at least 35 kg in 2018 based on the Adolescent Medicine Trials Network for HIV/AIDS Interventions 113 (Project PrEPare) study. This study identified the safety and feasibility of antiretroviral PrEP for adolescents aged 15 to 17 years in the U.S.11 For HIV prevention, patients take one tablet daily containing 200 mg emtricitabine and 300 mg tenofovir DF.10 Individuals must have a creatinine clearance (CrCl) of 30 mL/min or greater to take Truvada or its generic.10

     

    Preliminary evidence also suggests adult MSM who have infrequent sexual activity can take 2 doses of emtricitabine/tenofovir DF on an “on-demand” basis. Although not FDA approved for this indication, CDC guidelines recommend patients take 2 tablets (total dose emtricitabine 400 mg/tenofovir DF 600 mg) two to 24 hours prior to sexual activity, then one tablet each day for the next 2 days (i.e., 24 and 48 hours after initial dosing). In cases of continued sexual activity, patients should continue taking one tablet daily until 48 hours after the last sexual event.9 This dosing may be ineffective for other patient populations, as drug concentrations in colorectal tissues allows for more missed doses than vaginal concentrations.9

     

    In 2019, the FDA approved a second oral combination for HIV PrEP: emtricitabine 200 mg and tenofovir alafenamide (AF) 25 mg (brand name Descovy) for at-risk adolescents (age 12 years and older) and adults weighing at least 35 kg.12,13 This indication excludes women who have receptive vaginal sex because clinical trials did not assess this patient population. Individuals must have a CrCl of 60 mL/min or greater to take Descovy.13

     

    Both oral PrEP medication regimens offer the same level of protection (for indications evaluated), are dosed once daily, and have many similar adverse effects. However, emtricitabine-tenofovir DF has a higher risk of acute kidney injury and bone mineral density decline due to the tenofovir DF component.14 Serious adverse events from both medications are uncommon. Table 1 lists common and severe adverse effects associated with oral PrEP regimens. Although hepatotoxicity monitoring is not routinely recommended, pharmacists should advise patients to contact a provider if they experience signs and symptoms of liver dysfunction, including decreased appetite, nausea, stomach pain, yellowing of the skin or eyes, darkened urine, and light-colored stool.9 Both oral regimens include a Boxed Warning in their labeling for the possibility of severe acute exacerbations of hepatitis B and the need to use them in individuals confirmed to be HIV-negative immediately prior to initiating and at least every 3 months during use.10,13

     

    Table 1. Adverse Effects Associated with Available Oral PrEP Medications9,10,13

    Common
    Emtricitabine/tenofovir DF Headache, abdominal pain, and mild weight loss
    Emtricitabine/tenofovir AF Diarrhea
    Severe (both regimens)
    Adverse Effect Monitoring/Counseling
    Acute kidney injury/failure or worsening of chronic renal failure Evaluate kidney function before treatment (SCr, CrCl, eGFR) and monitor for signs and symptoms of kidney dysfunction (e.g., significantly reduced urine output)
    Lactic acidosis Monitor for clinical symptoms (physical discomfort, rapid breathing or problems breathing, muscle pain, and confusion), no routine labs suggested
    Bone issues associated with decreased BMD (e.g., pain, softening, thinning, fracture risk) Generally asymptomatic; refer to prescriber for fractures, pain, or other concerning bone-related symptoms. Recommend healthy diet with more vegetables and food rich in calcium, vitamin D and K. If needed, over the counter calcium supplement is recommended.
    Abbreviations: AF, alafenamide; BMD, bone mineral density; CrCl, creatinine clearance; DF, disoproxil fumarate; eGFR, estimated glomerular filtration rate; SCr, serum creatinine

     

    Injectable PrEP

    In December 2021, the FDA approved the first injectable therapy for HIV PrEP—cabotegravir extended-release injectable suspension (brand name Apretude)—for adolescents (12 years and older) and adults at risk of sexually-transmitted HIV infection who weigh at least 35 kg.15 The CDC released their HIV PrEP guidelines just prior to injectable cabotegravir’s approval, which may lead to confusion.9 Injectable cabotegravir is approved for adolescents and adults weighing at least 35 kg, but the guidelines only recommended it for adult persons.9,15 Also, injectable cabotegravir is approved to prevent sexually-acquired HIV, but CDC guidelines state that providers should evaluate people at risk due to injection drug use to see if they also are indicated for PrEP due to sexual activity and therefore eligible for injectable cabotegravir.9,15

     

    A provider administers two loading doses of cabotegravir 600 mg intramuscularly one month apart, followed by 600 mg intramuscularly every two months.15 There is a 7-day grace period for dosing. If patients are unable or do not receive their scheduled dose within seven days of when it is due, providers should consult the product information to assess if the patient remains a good candidate and restart dosing as recommended. If there is concern that the patient may not tolerate intramuscular cabotegravir, providers may opt to prescribe oral cabotegravir 30 mg daily as a trial for four weeks.15 If patients take the oral lead-in, the first injection should be scheduled within three days of the last oral dose and the second injection should still occur one month after the first.15

     

    The most common adverse effects of extended-release cabotegravir are injection site reactions (especially after the first few doses), fever, gastrointestinal upset (e.g., diarrhea, nausea, abdominal pain, decreased appetite), headache, myalgia, rash, fatigue, and sleep-related issues.9,15 Warnings and precautions for this medication include depressive disorders, hepatotoxicity, and hypersensitivity reactions.15 Cabotegravir’s labeling includes a Boxed Warning stating patients must have a confirmed negative HIV test before starting the drug and before each injection, as people with undiagnosed HIV who took cabotegravir have developed drug-resistant HIV variants.15 People who become infected with HIV while taking cabotegravir must stop the injections and switch to a complete HIV treatment regimen.15 It is also important to counsel patients that the drug will remain at low concentrations in their system for a long time (median times 44 and 67 weeks for men and women, respectively) even after discontinuing the drug.9 This low drug concentration could increase the risk of resistant virus if the patient is to become infected with HIV in that period.

     

    The FDA’s approval of a long-acting injectable for PrEP is significant progress toward ending the HIV epidemic, as it is the first therapy to prevent HIV that is not a daily oral pill. For PrEP to be effective, it requires a high level of patient adherence, but it is challenging for many patients to remember a daily medication.15 Cabotegravir extended-release injections every two months will be crucial in increasing PrEP adherence in high-risk individuals.15

     

    Ending the HIV epidemic requires adherence to published HIV testing recommendations, sexual health assessments, and STI screening and appropriate prevention education.2 Clinicians—including pharmacists—should be aware of the need for monitoring and follow up with HIV PrEP, listed in Figure 1. Pharmacists, as the most accessible healthcare professionals, can provide and reinforce education on sexual health (e.g., STI and HIV prevention) and recommend PrEP to those who may benefit. They should also encourage that patients combine different prophylaxis methods (e.g., condoms with PrEP) to improve protection based on CDC guidelines.9

    Figure showing different screening intervals for oral regimens versus injectable cabotegravir.

    Adolescents and young adults face many barriers that lower adherence rates, including lack of awareness of HIV risk, lack of parental understanding or support, safety and adverse effect concerns, and high cost. Pharmacists and pharmacy technicians have various responsibilities to combat these barriers. Pharmacists should help patients and caregivers understand the importance of taking PrEP medications as prescribed. Adherence education can include individualized counseling on medication use, adverse effect monitoring and management, reminder text messages, and computer- and phone-based support. Pharmacy staff can also help make these medications more affordable by working with other healthcare providers and insurance companies to access patient assistance programs and navigate prior authorization (see Tech Talk SIDEBAR).16

    Tech Talk: Helping Patients Afford PEP and PrEP17-21

    Most insurance companies (including Medicaid) are required to cover a PrEP option free of cost. Patients requiring PEP after a sexual assault may also be qualified for full or partial reimbursement. For example, New York state Medicaid will pay for PEP medications for non-occupational health exposures, including sexual assault. The CDC provides location-specific resources to help patients: https://www.cdc.gov/hiv/basics/pep/paying-for-pep.html. After a potential HIV exposure at work, patients usually receive workers’ compensation or their workplace health insurance pays for PEP. If patients cannot obtain insurance coverage, pharmacy technicians can collaborate with healthcare providers to prepare applications for PEP or PrEP through patient assistance programs.

     

    Patients in need of financial assistance—including those without insurance—may be eligible to receive free or low-cost PEP or PrEP medications. Manufacturers offer patient assistance programs to provide low-cost or free medications to people with low incomes. Companies have variable criteria that patients must meet to be eligible for enrollment. Applying to these programs take about five to ten minutes, and pharmacy staff should encourage prompt completion to avoid treatment delays. Patients covered under Medicaid or Medicare do not qualify for patient assistance programs or cost-sharing assistance programs.

     

    Generic versions of emtricitabine-tenofovir DF are less expensive than brand name products and are not usually available through company patient assistance programs or cost-sharing assistance programs. However, patients may qualify for support from the Patient Assistance Foundation, Needy Meds, and/or state PrEP assistance programs. Programs like Gilead's Advancing Access Form and NASTAD’s Patient Assistance Tool list step-by-step instructions on the forms themselves. Many brand name medications are covered by their respective pharmaceutical companies. For more information on patient assistance programs for HIV PrEP medications, please refer to https://nastad.org/prep-access/prep-assistance-programs.

     

     

    All medications approved for HIV PrEP are available by prescription only. Technicians who recognize these drugs can ensure the pharmacy dispenses and packages them appropriately (in their original packages to reduce the risk of contaminating the contents) and encourage adolescents and young adults to consult with the pharmacist as necessary (e.g., if they have questions, or would like education).

     

    PrEP medications require high adherence rates from patients. Technicians might identify patients’ difficulties with adherence during a patient’s medication reconciliation in the hospital or while speaking with a patient in the community pharmacy. Red flags include late refills or failure to pick up a refill, or presenting with prescription vials that have pills remaining when they should have already taken them all.

    PAUSE AND PONDER: How can pharmacy technicians help patients receive free or low-cost PEP and PrEP medications?

     

    POST-EXPOSURE PROPHYLAXIS

    Providers prescribe PEP to HIV-negative patients to prevent HIV infection after a possible exposure. After exposure to HIV, it takes two to four weeks for the virus to establish itself permanently in the body. After exposure, the body's immune system has a small window during which the viral load is small enough to be eradicated. Successful HIV PEP kills the virus before it can establish residency in the patient’s body.22 Patients must start a potent combination of HIV antiretrovirals immediately—ideally within 2 hours but no later than 72 hours after exposure.22 Every hour matters so the sooner the patient starts PEP, the lower the chance of becoming HIV infected. PEP requires a prescription from a healthcare provider and is highly effective (exceeding 80%) in preventing HIV.23

     

    PEP is only for emergency situations and should not take the place of other regular HIV prevention methods. Pharmacy staff should advise patients who frequently require PEP to talk to their provider to see if they qualify for PrEP. Some situations requiring HIV PEP include unplanned and/or unprotected sex or sexual assault, workplace exposures (e.g., a patient’s blood accidentally splashes into a healthcare worker’s eye), or needlestick injury with a contaminated needle.24

     

    Antiretroviral therapy for PEP involves a combination of three antiretroviral medications. According to the CDC, eligible patients should receive 28 days of PEP therapy.25 Table 2 lists the preferred antiretroviral regimens for PEP. Clinicians and patients with additional concerns or questions regarding optimal therapy options can call the National Clinical Consultations Center PEPline at (888) 448-4911.

     

    Table 2. HIV PEP Recommendations Based on Renal Function25, 26, 27

    Adolescents and young adults aged ≥ 13 years with: Medication
    Normal renal function

    (CrCl ≥ 60 mL/min)

    1) emtricitabine 200 mg/tenofovir DF 300 mg once daily with

    2) raltegravir 400 mg twice daily or dolutegravir 50 mg once daily*

    Renal dysfunction

    (CrCl ≤ 59 mL/min)

    1) zidovudine: Renally adjusted doses are based on oral doses of 160 mg/m2/dose every 8 hours and IV dose of 120 mg/m2/dose every 6 hours.

    GFR ≥10 mL/minute/1.73 m2 and continuous renal replacement therapy: No dosage adjustment required

    GFR <10 mL/minute/1.73 m2, intermittent hemodialysis, and peritoneal dialysis: Administer 50% of dose every 8 hours

     and

    2) lamivudine: <25 kg: There are no dosage adjustments provided in the manufacturer’s labeling; consider reducing the dose or increasing the dosing interval; use with caution and monitor closely.

    ≥25 kg:

    CrCl ≥50 mL/minute: No adjustment necessary.

    CrCl 30 to 49 mL/minute: 150 mg once daily.

    CrCl 15 to 29 mL/minute: 150 mg first dose, then 100 mg once daily.

    CrCl 5 to 14 mL/minute: 150 mg first dose, then 50 mg once daily.

    CrCl <5 mL/minute: 50 mg first dose, then 25 mg once daily.

    No additional dosing is required after routine (4 hour) hemodialysis or peritoneal dialysis.

     with

    3) raltegravir 400 mg twice daily or dolutegravir 50 mg once daily*

    *Dosing is the same for both normal renal function and renal dysfunction

    CrCl, creatinine clearance; DF, disoproxil fumarate

    PAUSE & PONDER: What are the most important counseling points for pharmacists to relay to patients about PEP and PrEP?

    Headache, gastrointestinal effects (e.g., nausea, diarrhea, vomiting), and fatigue are common adverse effects of PEP regimens. In addition, clinicians should note some medication-specific adverse effects and contraindications28:

    • Tenofovir is contraindicated in patients with renal dysfunction (≤ 30 mL/min for DF formulation, ≤ 60 mL/min with AF formulation)
    • Emtricitabine can cause a hyperpigmented rash or skin discoloration
    • Raltegravir and dolutegravir should be administered either two hours before or six hours after cation-containing products (e.g., calcium, magnesium, iron, multivitamins) because they can reduce the medications’ absorption (it is important to ask patients about these specifically, as they can be obtained over-the-counter)
    • Zidovudine can cause anemia and neutropenia
    • Lamivudine should not be administered with emtricitabine
    • Tenofovir, emtricitabine, and lamivudine can be used in patients infected with hepatitis B, but patients will need liver function monitoring upon discontinuation because withdrawal may cause or exacerbate acute hepatitis

     

    Patients respond differently to medications and not everybody experiences adverse effects. If patients develop life-threatening adverse effects, they need emergency attention. Subsequently, primary prescribers will need to adjust treatment plans as needed.

     

    Pharmacists must emphasize the importance of patients taking PEP medications as prescribed and remind patients picking up these prescriptions to follow up with their providers. Further, counseling should include that these medications should be taken at the same time every day to optimize effectiveness. It is also important to counsel patients taking medications for PEP, that if they miss any doses, the likelihood of becoming infected with HIV is greater.22 Technicians should be sure to ask patients who receive PEP if they would like to talk to the pharmacist. One possible communication could be, “This is important medication, and the pharmacist may be able to answer questions you don’t even know you have!” Prompts like this can provide patient privacy while encouraging them to spend some time with the pharmacist.

     

    Prescribers monitor patients on PEP at baseline and during the months following exposure. It is important to reinforce that patients require testing for HIV after they complete the medication regimen to ensure it was effective. Table 3 describes the CDC-recommended laboratory monitoring schedule for HIV PEP.28

     

    Table 3. HIV PEP Required Laboratory Monitoring28

    Monitoring Reason(s) Time Period
    HIV antigen/antibody Ensure the patient does not already have HIV (ineligible for PEP) and make sure PEP is effective after use Baseline, 4-6 weeks after exposure, and at 3 months after exposure*
    Hepatitis B and C Pre-existing hepatitis infection may change therapy recommendations or monitoring Baseline
    Serum creatinine Evaluate baseline kidney function for initial therapy choice and determining correct dosing if significant impairment exists and ensure that PEP is not causing kidney injury Baseline and 4-6 weeks after exposure if receiving emtricitabine/tenofovir and integrase-based regimen (e.g., bictegravir, cabotegravir, dolutegravir, elvitegravir, raltegravir)
    Alanine transaminase and aspartate aminotransferase Liver function could affect therapy decisions, especially if baseline hepatitis exists Baseline and 4-6 weeks after exposure if receiving emtricitabine/tenofovir with an integrase inhibitor (e.g., bictegravir, cabotegravir, dolutegravir, elvitegravir, raltegravir)
    Pregnancy test Pregnancy status should be incorporated into therapy decisions Baseline and 4-6 weeks after exposure
    Bacterial STIs Identify any potential co-infections and ensure optimal, prompt therapy Baseline (if not done at baseline or if symptomatic, complete at 4-to-6-week follow-up)

    *additional testing at 6 months indicated if Hepatitis C acquired during exposure

     

    HIV-RELATED STIGMA

    HIV remains a highly stigmatized condition in both adults and adolescents. HIV stigma is discrimination based on negative attitudes and beliefs about the disease and the people who have it. Due to HIV’s long-standing history of prejudice and labeling, patients may have feelings of shame, fear of disclosure, isolation, and despair. This discourages individuals living with HIV from accessing treatment or staying in care, often affecting their health. Additionally, state laws concerning minors’ rights to give informed consent to receive HIV diagnosis or treatment vary across the U.S. Mental and behavioral health is often neglected, which can increase the burden on people living with HIV infection.

     

    It is important that the healthcare team recognizes and actively addresses this stigma using interventions that ensure the well-being of affected patients. The CDC lays out two guidelines to help address the issues of problematic language and minors’ ability to consent:

     

    CONCLUSION

    Adolescents and young adults who participate in high-risk behaviors (e.g., unprotected sex, injectable drug use) are at increased risk for contracting HIV. HIV PrEP and PEP are important medical advances that decrease the risk of HIV infection for uninfected patients. CDC guidelines provide up-to-date recommendations on the medications used for PrEP and PEP. Pharmacists who dispense these medications should be prepared to educate and counsel adolescent and young adult patients at risk of HIV on the appropriate use of PrEP and PEP. Pharmacy technicians can provide significant assistance to patients obtaining HIV PrEP and PEP to ensure these medications are affordable. They can also be vigilant to refer patients obtaining these prescriptions to the pharmacist for important counseling and education.

     

    Pharmacist Post Test (for viewing only)

    PHARMACIST POSTTEST

    Pharmacist Posttest:

    Learning Objectives
    1. Discuss the prevalence of HIV/AIDS in humans and associated stigma in the adolescent and young adult population
    2. Identify risk factors for HIV infection in adolescent and young adults
    3. Review pre-/post-exposure prophylaxis methods for HIV prevention in the adolescent/young adult population
    4. Maximize the pharmacists’ role in HIV prevention in the adolescent/young adult population

    1. GB is a 17-year-old who volunteers at a local nursing home after school. She recently experienced a needlestick injury with a contaminated needle. She asks you if she is eligible to receive PEP. Within how many hours after the injury should GB receive PEP?
    A. 96 hours
    B. 72 hours
    C. 128 hours

    2. Which of the following barriers contributes to lower PrEP adherence rates in adolescents and young adults?
    A. Lack of HIV risk awareness
    B. Parental involvement in therapy
    C. Disregard for safety and adverse effects

    3. According to the 2021 Preexposure Prophylaxis for the Prevention of HIV Infection in the U.S. clinical practice guidelines, clinicians should offer PrEP to minors who fit into which of the following categories:
    A. HIV negative, cisgender women who use condoms regularly
    B. Sexually active, HIV negative MSM with HIV-positive partners
    C. People living with HIV who inject drugs and have history of STIs

    4. According to the CDC’s guidelines which PEP medication is appropriate for a patient with a CrCl of 50 mL/min?
    A. Zidovudine
    B. Cabotegravir
    C. Emtricitabine

    5. Which of the following is TRUE regarding high school students’ behaviors that increase HIV risk?
    A. Most are tested for HIV at every pediatrician appointment
    B. About half report not using a condom during their last sexual intercourse
    C. About half report drinking alcohol prior to their last sexual encounter

    6. A prescriber reaches out to you for help determining the most appropriate PEP therapy for a 15-year-old female who was sexually assaulted 12 hours ago. She has normal renal function and weighs 100 lbs. She takes hormonal birth control pills regularly and reports good adherence. Which of the following is the BEST recommendation?
    A. Zidovudine 300 mg/lamivudine 150 mg + raltegravir 400 mg twice daily for 2 weeks
    B. Cabotegravir 30 mg daily for 4 weeks, then 600 mg intramuscularly once
    C. Emtricitabine 200 mg/tenofovir 300 mg + dolutegravir 50 mg once daily for 4 weeks

    7. Which of the following is TRUE regarding cabotegravir extended-release injectable suspension for PrEP?
    A. Patients require a confirmed negative HIV test each injection
    B. Patients with injection site reactions can take cabotegravir 30 mg orally instead
    C. Patients must self-inject intramuscularly every 3 months

    Pharmacy Technician Post Test (for viewing only)

    PHARMACY TECHNICIAN POSTTEST

    Pharmacy Technician Posttest:

    Learning Objectives
    1. Recall the prevalence of HIV/AIDS among adolescents and young adults and its associated stigma
    2. List high-risk activities for HIV exposure
    3. Describe available patient assistance programs & cost assistance programs for pre- and post-exposure HIV prophylaxis
    4. Identify antiretrovirals used for pre-/post-exposure HIV prophylaxis in the adolescent and young adult population

    1. AB comes into the pharmacy to pick up over-the-counter calcium supplements. You see that she recently started taking PEP for an HIV exposure at work. Which of the following PEP medications would alert you to refer AB to the pharmacist?
    A. Raltegravir
    B. Zidovudine
    C. Lamivudine

    2. Who defines the criteria that patients must meet for patient assistance programs?
    A. Pharmacists at community pharmacies enforce standardized criteria for all programs
    B. Manufacturers or pharmaceutical companies each determine their own criteria
    C. Medicare enforces standardized criterion for all patient assistance programs

    3. GB is a 17-year-old who volunteers at a local nursing home after school. She recently experienced a needlestick injury with a contaminated needle. Within how many hours after the injury should GB receive PEP?
    A. 96 hours
    B. 72 hours
    C. 128 hours

    4. What is the suggested duration of HIV PEP therapy?
    A. 28 days
    B. 6 weeks
    C. 4 months

    5. According to the American Academy of Pediatrics, what percentage of youth with HIV are undiagnosed?
    A. More than 60%
    B. More than 40%
    C. Less than 30%

    6. Which of the following is TRUE regarding high school students’ behaviors that increase HIV risk?
    A. Most are tested for HIV at every pediatrician appointment
    B. About half report drinking alcohol prior to their last sexual encounter
    C. About half report not using a condom during their last sexual intercourse

    7. Which of the following BEST describes insurance coverage and patient assistance programs for PrEP?
    A. Most patients with insurance should have zero co-pay for at least one form of PrEP
    B. Patient assistance programs generally only cover generic forms of PrEP
    C. Uninsured patients do not qualify for any patient assistance programs for PrEP

    References

    Full List of References

    REFERENCES

      References:

      1. Centers for Disease Control and Prevention. About HIV. Updated June 30, 2022. Accessed September 14, 2022. https://www.cdc.gov/hiv/basics/whatishiv.html
      2. Zhou, Mo, et al. Pre-exposure prophylaxis (PrEP) prescriptions among individuals at high risk for HIV in the United States, 2012-2018. IDWeek 2021; September 29-October 3, 2021. . Accessed October 18, 2022. Available at 1799149-1632773807.pdf (rackcdn.com)
      3. Hosek S, Henry-Reid L. PrEP and adolescents: The role of providers in ending the AIDS epidemic. Pediatrics. 2020;145(1):e20191743. doi:10.1542/peds.2019-1743
      4. Impact on Racial and Ethnic Minorities. HIV.gov Web site. https://www.hiv.gov/hiv-basics/overview/data-and-trends/impact-on-racial-and-ethnic-minorities.Accessed October 18, 2022
      5. Szucs LE, Lowry R, Fasula AM, et al. Condom and contraceptive use among sexually active high school students - Youth risk behavior survey, United States, 2019. MMWR Suppl. 2020;69(1):11-18. doi:10.15585/mmwr.su6901a2.
      6. Martinez GM, Abma JC. Sexual Activity, Contraceptive Use, and Childbearing of Teenagers Aged 15-19 in the United States. NCHS Data Brief. 2015;(209):1-8.
      7. Centers for Disease Control and Prevention. Pre-exposure prophylaxis (PrEP). Updated July 5, 2022. Accessed September 14, 2022. https://www.cdc.gov/hiv/clinicians/prevention/prep.html
      8. Pre-Exposure Prophylaxis. HIV.gov. Updated January 7, 2022. Accessed April 2, 2022. https://www.hiv.gov/hiv-basics/hiv-prevention/using-hiv-medication-to-reduce-risk/pre-exposure-prophylaxis
      9. Centers for Disease Control and Prevention. Preexposure prophylaxis for the prevention of HIV infection in the United States—2021 update: A clinical practice guideline. March 2018. Accessed March 2, 2022. https://www.cdc.gov/hiv/pdf/risk/prep/cdc-hiv-prep-guidelines-2021.pdf
      10. Truvada [prescribing information]. Gilead Sciences; 2020. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021752s061lbl.pdf
      11. Hosek SG, Landovitz RJ, Kapogiannis B, et al. Safety and feasibility of antiretroviral preexposure prophylaxis for adolescent men who have sex with men aged 15 to 17 years in the United States. JAMA Pediatrics. 2017;171(11):1063-1071. doi:10.1001/jamapediatrics.2017.2007
      12. U.S. Food and Drug Administration. FDA approves second drug to prevent HIV infection as part of ongoing efforts to end the HIV epidemic. October 3, 2019. Accessed March 2, 2022. https://www.fda.gov/news-events/press-announcements/fda-approves-second-drug-prevent-hiv-infection-part-ongoing-efforts-end-hiv-epidemic
      1. Descovy [prescribing information]. Gilead; 2021. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/208215s019lbl.pdf
      2. Havens PL, Stephensen CB, Van Loan MD, et al. Decline in bone mass with tenofovir disoproxil fumarate/emtricitabine is associated with hormonal changes in the absence of renal impairment when used by HIV-uninfected adolescent boys and young men for HIV preexposure prophylaxis. Clin Infect Dis. 2017;64(3):317-325. doi:10.1093/cid/ciw765
      3. Apretude [prescribing information]. ViiV Healthcare; 2021. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/215499s000lbl.pdf
      4. Velloza J, Kapogiannis B, Bekker LG, et al. Interventions to improve daily medication use among adolescents and young adults: what can we learn for youth pre-exposure prophylaxis services?. AIDS. 2021;35(3):463-475. doi:10.1097/QAD.0000000000002777
      5. Centers for Disease Control and Prevention. Paying for PrEP. Updated June 6, 2022. Accessed September 14 ,2022. https://www.cdc.gov/hiv/basics/prep/paying-for-prep/index.html
      6. New York State Department of Health. Payment options for post-exposure prophylaxis following non-occupational exposures including sexual assault (nPEP). May 2013. Accessed April 1, 2022. https://www.health.ny.gov/diseases/aids/providers/standards/docs/payment_options_npep.pdf
      7. New York State Department of Health. Payment options for adults and adolescents for post exposure prophylaxis (PEP) following sexual assault. October 2021. Accessed April 25, 2022. https://www.health.ny.gov/diseases/aids/general/pep/docs/sexual_assault.pdf
      8. Centers for Disease Control and Prevention. Paying for PEP. Updated July 13, 2022. Accessed February 24, 2022. https://www.cdc.gov/hiv/basics/pep/paying-for-pep.html
      9. NASTAD. Pharmaceutical Company Patient assistance programs and cost-sharing assistance programs for pre-exposure prophylaxis (PrEP) and post-exposure prophylaxis (PEP). May 2021. Accessed February 23, 2022. https://nastad.org/sites/default/files/2021-11/PDF-PrEP-PEP-Pharma-Co-Patient-Assistance.pdf
      10. DeHaan E. Post-exposure prophylaxis (PEP) to prevent HIV infection. National Center for Biotechnology Information. Published June 2020. Accessed April 14, 2022. https://www.ncbi.nlm.nih.gov/books/NBK562734/
      11. Leonard J. HIV symptoms timeline: Stages, preventing progression, and outlook. Medical News Today. Updated November 22, 2020. Accessed March 15, 2022. https://www.medicalnewstoday.com/articles/316056
      12. Post-exposure prophylaxis. HIV.gov. Updated April 28, 2021. Accessed February 14, 2022. https://www.hiv.gov/hiv-basics/hiv-prevention/using-hiv-medication-to-reduce-risk/post-exposure-prophylaxis
      13. CATIE. Post-exposure prophylaxis (PEP). 2019. Accessed March 15, 2022. https://www.catie.ca/fact-sheets/prevention/post-exposure-prophylaxis-pep
      14. 26. Aronoff GR, Bennett WM, Berns JS, et al, Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children, 5th ed. Philadelphia, PA: American College of Physicians; 2007, p 82.
      15. Epivir (lamivudine) [prescribing information]. Shire Pharmaceuticals Group plc. 2017. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020564s37_020596s036lbl.pdf
      16. Centers for Disease Control and Prevention. Updated guidelines for antiretroviral postexposure prophylaxis after sexual, injection drug use, or other nonoccupational exposure to HIV—United States, 2016. Accessed March 13, 2022. https://www.cdc.gov/hiv/pdf/programresources/cdc-hiv-npep-guidelines.pdf

       

       

       

       

       

      Stop the Bite: Uncover the Answers to Malaria and Dengue Fever

      Learning Objectives

       

      After completing this knowledge-based continuing education activity, pharmacists will be able to

      • RECALL symptoms associated with dengue fever and malaria
      • DESCRIBE emerging information about dengue and malaria vaccines
      • ASSOCIATE dengue fever and malaria vaccines for specific patients

      After completing this knowledge-based continuing education activity, pharmacy technicians will be able to

      •      RECALL symptoms associated with dengue fever and malaria
      •      DESCRIBE emerging information about dengue and malaria vaccines
      •      MATCH  dengue fever and malaria vaccines by storage requirements

      Cartoon representation of a mosquito.

       

      Release Date: February 1, 2023

      Expiration Date: February 1, 2026

      Course Fee

      Pharmacists: $4

      Pharmacy Technicians: $2

      There is no grant funding for this CE activity

      ACPE UANs

      Pharmacist: 0009-0000-23-002-H06-P

      Pharmacy Technician: 0009-0000-23-002-H06-T

      Session Codes

      Pharmacist:  23YC02-MTX44

      Pharmacy Technician:  23YC02-XTM62

      Accreditation Hours

      0.5 hours of CE

      Accreditation Statements

      The University of Connecticut School of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.  Statements of credit for the online activity ACPE UAN 0009-0000-23-002-H06-P/T  will be awarded when the post test and evaluation have been completed and passed with a 70% or better. Your CE credits will be uploaded to your CPE monitor profile within 2 weeks of completion of the program.

       

      Disclosure of Discussions of Off-label and Investigational Drug Use

      The material presented here does not necessarily reflect the views of The University of Connecticut School of Pharmacy or its co-sponsor affiliates. These materials may discuss uses and dosages for therapeutic products, processes, procedures and inferred diagnoses that have not been approved by the United States Food and Drug Administration. A qualified health care professional should be consulted before using any therapeutic product discussed. All readers and continuing education participants should verify all information and data before treating patients or employing any therapies described in this continuing education activity.

      Faculty

      Jessica Bylyku, BS
      PharmD Candidate 2024
      UConn School of Pharmacy
      Storrs, CT

                                                

      Kelsey Giara, PharmD
      Freelance Medical Writer
      Pelham, NH

       

      Melody White
      PharmD Candidate 2025
      UConn School of Pharmacy
      Storrs, CT

      Faculty Disclosure

      In accordance with the Accreditation Council for Pharmacy Education (ACPE) Criteria for Quality and Interpretive Guidelines, The University of Connecticut School of Pharmacy requires that faculty disclose any relationship that the faculty may have with commercial entities whose products or services may be mentioned in the activity.

      Dr. Giara, Jessica Bykylu and Melody White do not have any relationships with ineligible companies and therefore have nothing to disclose.

       

      ABSTRACT

      Malaria and dengue (pronounced deng-ee) fever are not new diseases, but given the emergence of new vaccines, it is critical that pharmacists and pharmacy technicians increase their familiarity with them. These illnesses are both transmitted by mosquitos, but malaria is caused by Plasmodium parasites while dengue fever is a viral disease caused by dengue virus. The United States is not a malaria- or dengue-endemic country, but travel to other countries puts people at risk of these conditions. Pharmacy teams should be prepared to identify potential cases and refer patients for appropriate vaccination or treatment when appropriate.

      CONTENT

      Content

      INTRODUCTION

      Malaria cases in 2020 totaled an estimated 241 million, leading to more than 600,000 deaths, mostly in Africa.1 Direct costs of malaria prevention and treatment in the United States (U.S.) total about $12 billion annually, excluding the toll it takes on affected individuals and their families.1 The World Health Organization (WHO) reports that between 100 to 400 million people are infected with dengue fever each year.2 About 80% of cases are mild and asymptomatic, but dengue fever can progress to “severe dengue,” which is classified as a medical emergency requiring immediate medical care.2,3

       

      Mosquitos, Malaria, and Dengue – Oh My!

      Plasmodium parasites—common to tropical areas (e.g., Africa, South America, the Caribbean Islands, South Asia)—cause malaria.1 Most commonly, malaria is transmitted through the bite of infected mosquitoes, specifically the Anopheles species, during local outbreaks. There is also a term coined “airport malaria,” describing disease that is transported from an infected country to a non-infected country.4 Congenital malaria occurs when mothers infected with the disease transmit parasites to the child during pregnancy or birth.4 Although rare, prompt diagnosis is crucial to ensure infected neonates and infants survive. Transfusion-transmitted malaria is also possible where blood recipients can be infected with malaria accidently. There are no approved tests to screen blood donations for malaria, only questioning of prospective donors.4 Although rare in the U.S., complications are severe and organizations should take action to prevent potentially-infected individuals from donating.

       

      Patients with malaria generally present with fever, chills/sweating, headache, and weakness within 10 to 15 days of infection.5 Diarrhea, abdominal pain, and cough are also possible. As malaria progresses, patients develop a classic paroxysm (i.e., symptoms that come and go) comprising three stages6:

      1. 15-to-60-minute cold stage (shivering and feeling cold)
      2. 2-to-6-hour hot stage (fevers up to nearly 106°F; flushed, dry skin; and often headache, nausea, and vomiting)
      3. 2-to-4-hour sweating stage (rapid drop in fever and sweating)

       

      Missed or delayed malaria diagnosis can lead to potentially fatal complicated disease manifesting as severe anemia, renal failure, altered consciousness, and multisystem organ failure.6 Clinicians diagnose malaria via a blood smear test. Although rapid and polymerase chain reaction (PCR) tests are available, medical professionals confirm diagnosis through microscopic blood smear examination.7

       

      Dengue fever is a viral disease caused by mosquitos—mainly females from the Aedes aegypti and Ae. albopictus species—carrying dengue virus (also known as DENV).2 Four DENV serotypes exist, so it is possible to contract the disease four times. The virus can be transmitted through mosquito bite, from pregnant mother to child, and via infected blood products/organ donations and infusions. Transovarial transmission within mosquitoes (from parent to offspring) has also been noted.2

       

      Most dengue cases are asymptomatic or mild and fatalities are rare, but increasing severity can be life-threatening.2,3 Providers should suspect dengue when a high fever (104°F or greater) is accompanied by any two of the following symptoms2,3:

      • severe headache
      • pain behind the eyes
      • muscle/joint/bone pain
      • nausea/vomiting
      • swollen glands
      • rash

       

      This febrile phase lasts about 2 to 7 days, and most people recover after about a week.2,3 Severe dengue is a potentially fatal complication due to plasma leakage, fluid accumulation, respiratory distress, severe bleeding, or organ impairment.2 Patients are at risk of severe dengue symptoms about 3 to 7 days after initial symptoms appear.2 As fever drops to below 100°F, patients enter a “critical phase” for 24 to 48 hours. Warning signs to watch for during the critical phase include2

      • severe abdominal pain
      • rapid breathing
      • blood in vomit, stool, gums, or nose
      • persistent vomiting
      • restlessness/fatigue

       

      Clinicians use commercially available PCR or rapid diagnostic tests to confirm dengue diagnosis.2 Enzyme-linked immunosorbent assays are also available to confirm active or previous infections.

       

      Global Implications  

      Beyond clinical symptoms, malaria and dengue fever inflict social and financial loss for diagnosed individuals and the countries tasked with treating affected populations. Some examples of the indirect burden of these mosquito-borne diseases include1

      • expenses for traveling and receiving treatment
      • absences from work/school
      • burial expenses in cases of death
      • purchases of medication and supplies
      • public health interventions (e.g., insecticide spraying, bed nets)
      • opportunity loss for tourism

       

      Populations at increased risk of contracting malaria include infants, children younger than 5 years, pregnant women, immunosuppressed patients, and migrant workers or traveling populations.5 There is also concern that certain mosquitoes are resistant to insecticide, and by migrating throughout the world they can spread malaria to urban populations.8 Researchers have identified Anopheles gambiae mosquitoes, originally found in India and Iran, as insecticide-resistant. These are projected to put nearly 126 million people in African cities at risk for contracting malaria.8

       

      Populations most vulnerable to contracting dengue fever include pregnant women and children.3 Many asymptomatic or mild dengue cases go unreported. WHO reports most of the dengue burden occurs in Asia, and the number of cases has steadily increased to just over 5 million in 2019.2

       

      PREVENTION AND TREATMENT

      Following prevention and treatment guidelines are crucial to lower transmission rates of dengue fever and malaria.

       

      Dengue Fever

      WHO states that countries should be aware of community mosquito presence and develop active mosquito and virus surveillance to prevent further disease spread.2 They should also remain knowledgeable about the number of infected individuals.

       

      The dengue vaccine (Dengvaxia) has been licensed in other countries since 2015, but the U.S. Food and Drug Administration (FDA) approved the vaccine in 2019.2 WHO recommends people aged 9 to 45 years be vaccinated, but Dengvaxia is only FDA approved for patients 9 to 16 years old with a history of previous infection who live in high-risk areas. As a live-attenuated vaccine, it is contraindicated in individuals with severe immunodeficiency.2 Children receiving Dengvaxia need a 3-dose series administered subcutaneously with doses separated by 6 months.9 Providers should store the vaccine in the refrigerator.10 After reconstitution, it should be administered immediately or stored in the refrigerator and used within thirty minutes.

       

      WHO and the FDA only recommend Dengvaxia for patients with a history of dengue virus infection.10,11 This is based on clinical trial evidence that the vaccine is efficacious and safe in patients with a history of previous DENV infection because a subsequent infection is more serious and life-threatening than the first.11 They also advise countries using the vaccine to control viral spread to implement pre-vaccination screening to confirm previous infection.

       

      As no dengue-specific treatment is available, providers should treat infected patients symptomatically with acetaminophen, rest, and fluids.2 Patients with dengue fever should avoid non-steroidal anti-inflammatory drugs (e.g., ibuprofen, aspirin) because they thin the blood. Given the risk of hemorrhage in this disease, blood thinners may exacerbate the problem.2

       

      Malaria

      WHO recommends that countries engage in vector control and surveillance for the spread of malarial disease.5 Malaria vaccines have been in development for decades, but no malaria vaccine is available in the U.S.12 In 2021, however, WHO recommended a new malaria vaccine (Mosquirix) for children aged older than 5 months who live in areas with moderate to high transmission of P. falciparum.13 The vaccine is only recommended for children as malaria is one of the main killers of children younger than 5 years in countries with moderate or high rates of malaria.14 WHO also recommends giving the vaccine seasonally in countries where malaria transmission is high during certain seasons.13

       

      Initial Mosquirix pilot studies are ongoing, and more widespread vaccine rollout is expected in 2023. For now, people in the U.S. traveling to malaria-endemic countries continue to use oral medications as chemoprophylaxis (i.e., to prevent the disease), including atovaquone/proguanil, chloroquine, doxycycline, mefloquine, primaquine, and tafenoquine.15

       

      Clinicians administer Mosquirix as a 4-dose schedule.16 The vaccine’s adverse effects are pain and swelling at the injection site and fever.17 Providers should store the vaccine in the refrigerator. After reconstitution it should be administered immediately or stored in the refrigerator and used within 6 hours.16

       

      Malaria treatment involves the use of antimalarial drugs based on four main factors15:

      • Infection severity: Malaria infection is either considered uncomplicated (effectively treated with oral antimalarials) or severe (requiring aggressive intravenous antimalarial therapy).
      • Infecting Plasmodium species: P. falciparum and P. knowlesi infections can cause rapidly progressive severe illness or death, necessitating urgent therapy initiation, while other species are less likely to cause severe disease. P. vivax and P. ovale infections also require treatment for hypnozoites (parasites that lay dormant in the liver and then re-awaken to become active infectants).
      • Drug susceptibility: In addition to disease severity differences, Plasmodium species also have different drug susceptibilities, so providers select an antimalarial therapy based on the species of the infecting parasite. If the species cannot be determined, patients must initiate antimalarial treatment against chloroquine-resistant P. falciparum as soon as possible.
      • Previous antimalarial use: Patients using antimalarial medication as chemoprophylaxis, should not receive that same drug or drug combination to treat malaria infection unless no other options are available.

       

      CONCLUSION

      Pharmacists and pharmacy technicians should be familiar with the signs and symptoms of malaria and dengue fever to inform patients when these conditions are suspected and about their appropriate treatment. Pharmacy teams who suspect a case of malaria or dengue fever should refer patients for medical attention and contact their local or state health department.

       

       

       

       

      Pharmacist Post Test (for viewing only)

      PHARMACIST POSTTEST

      Learning Objectives
      ● RECALL symptoms associated with dengue fever and malaria
      ● DESCRIBE emerging information about dengue and malaria vaccines
      ● OPTIMIZE dengue fever and malaria vaccines for specific patients

      1. Which of the following is TRUE?
      A. Dengue fever symptoms are always severe and most patients die
      B. Malaria presents as a cold stage, hot stage, and sweating stage
      C. Pain behind the eyes is a warning sign for malaria

      2. Which of the following is TRUE regarding the malaria vaccine?
      A. WHO recommends it for children 5 months and older who live in endemic areas
      B. It is FDA approved for patients 9 to 16 years old with a history of previous infection
      C. Clinicians administer it as a 3-dose series with each dose separated by 6 months

      3. A patient comes to the pharmacy indicating she and her family are being transferred to a country where dengue is common. She wants to have her three children who are ages 3, 5, and 7 vaccinated for dengue before they move. What is the BEST thing to tell her?
      A. We should schedule your children to be vaccinated about six weeks before you plan to move so they develop antibodies before you actually relocate.
      B. We only vaccinate children who have already had dengue because a second infections is more serious and life-threatening than the first.
      C. Wait until you arrive in the country because they will want to do pre-vaccination screening to confirm your children have not been infected previously.

      Pharmacy Technician Post Test (for viewing only)

      PHARMACY TECHNICIAN POSTTEST

      Learning Objectives
      ● RECALL symptoms associated with dengue fever and malaria
      ● DESCRIBE emerging information about dengue and malaria vaccines
      ● CLASSIFY dengue fever and malaria vaccines by storage requirements

      1. Which of the following is TRUE?
      A. Dengue fever symptoms are always severe and most patients die
      B. Malaria presents as a cold stage, hot stage, and sweating stage
      C. Pain behind the eyes is a warning sign for malaria

      2. Which of the following is TRUE regarding the malaria vaccine?
      A. WHO recommends it for children 5 months and older who live in endemic areas
      B. It is FDA approved for patients 9 to 16 years old with a history of previous infection
      C. Clinicians administer it as a 3-dose series with each dose separated by 6 months

      3. A patient at your pharmacy is receiving the dengue fever vaccine. The patient’s mother asks you if they can use the restroom before the pharmacist administers the vaccine. You look over to see that the pharmacist has just finished reconstituting Dengvaxia for this patient. Which of the following is the BEST response?
      A. Advise the mother not to leave the pharmacy waiting area, as the pharmacist needs to administer this vaccine immediately or it will expire
      B. Advise the mother to take her daughter to the restroom, and the pharmacist can administer this vaccine within 6 hours as long as it’s refrigerated
      C. Advise the mother to take her daughter to the restroom but return within 30 minutes, and ensure the pharmacist refrigerates the reconstituted vaccine

      References

      Full List of References

      REFERENCES

      1. Centers for Disease Control and Prevention. Malaria’s Impact Worldwide. Updated December 16, 2021. Accessed November 30, 2022. https://www.cdc.gov/malaria/malaria_worldwide/impact.html
      2. World Health Organization. Dengue and severe dengue. Updated January 10, 2022. Accessed November 1, 2022. https://www.who.int/news-room/fact-sheets/detail/dengue-and-severe-dengue
      3. Centers for Disease Control and Prevention. Dengue. Updated August 3, 2022. Accessed November 1, 2022. https://www.cdc.gov/dengue/index.html
      4. Centers for Disease Control and Prevention. Parasites – Malaria. Updated August 19, 2022. Accessed November 1, 2022. https://www.cdc.gov/parasites/malaria/index.html
      5. World Health Organization. Malaria. Updated July 26, 2022. Accessed November 1, 2022. https://www.who.int/news-room/fact-sheets/detail/malaria
      6. Crutcher JM, Hoffman SL. Chapter 83: Malaria. In: Baron S, ed. Medical Microbiology. 4th ed. University of Texas Medical Branch at Galveston; 1996. Accessed November 1, 2022. https://www.ncbi.nlm.nih.gov/books/NBK8584/
      7. Stanford Health Care. Malaria diagnosis. Accessed November 1, 2022. https://stanfordhealthcare.org/medical-conditions/primary-care/malaria/diagnosis.html
      8. American Society of Tropical Medicine and Hygiene. Invasive mosquitos – Anopheles stephensi in Ethiopia. November 1, 2022. Accessed November 30, 2022. https://astmhpressroom.wordpress.com/annual-meeting-2022/anopheles-stephensi-in-ethiopia/
      9. Centers for Disease Control and Prevention. Dengue Vaccine VIS. Updated December 17, 2021. Accessed November 29, 2022. https://www.cdc.gov/vaccines/hcp/vis/vis-statements/dengue.html
      10. Dengvaxia [prescribing information]. Sanofi Pasteur; 2019.
      11. Ask the Experts: Dengue. Immunize.org. Updated February 16, 2022. Accessed November 21, 2022. https://www.immunize.org/askexperts/experts_dengue.asp
      12. Centers for Disease Control and Prevention. Malaria: Vaccines. Updated October 7, 2021. Accessed December 2, 2022. https://www.cdc.gov/malaria/malaria_worldwide/reduction/vaccine.html
      13. Q&A on RTS,S malaria vaccine. World Health Organization. Updated April 21, 2022. Accessed November 30, 2022. https://www.who.int/news-room/questions-and-answers/item/q-a-on-rts-s-malaria-vaccine
      14. UNICEF. Millions more children to benefit from malaria vaccine as UNICEF secures supply. August 16, 2022. Accessed November 22, 2022. https://www.unicef.org/press-releases/millions-more-children-benefit-malaria-vaccine-unicef-secures-supply
      15. Centers for Disease Control and Prevention. Treatment of Malaria: Guidelines for Clinicians (United States). Updated September 30, 2022. Accessed November 30, 2022 https://www.cdc.gov/malaria/diagnosis_treatment/clinicians1.html
      16. Mosquirix (Product Information). European Medicines Agency. Updated January 8, 2022. Accessed November 30, 2022. https://www.ema.europa.eu/en/documents/outside-eu-product-information/mosquirix-product-information_en.pdf
      17. World Health Organization. Malaria: The malaria vaccine implementation programme (MVIP). March 2, 2020. Accessed November 30, 2022. https://www.who.int/news-room/questions-and-answers/item/malaria-vaccine-implementation-programme

       

       

      Time to Learn about New Cardiac Drugs-RECORDED WEBINAR

      About this Course

      This course is a recorded (home study version) of the CE Finale Encore Webinars.

       

      Learning Objectives

      Upon completion of this application based CE Activity, a pharmacist will be able to:

      • Select the appropriate first and adjunctive therapies for LDL lowering in patients with differing risks according to guideline recommendations
      • Compare and contrast the mechanism of action and potential utility of the new LDL lowering drugs bempedoic acid and inclisirin versus traditional options
      • Describe hypertrophic cardiomyopathy and its risks
      • Identify the mechanism of action and potential utility of mavacamten versus agents currently recommended in guidelines

      Release and Expiration Dates

      Released:  December 16, 2022
      Expires:  December 16, 2025

      Course Fee

      $17 Pharmacist

      ACPE UAN

      0009-0000-22-056-H01-P

      Session Code

      22RW56-TXJ88

      Accreditation Hours

      1.0 hours of CE

      Additional Information

       

      How to Complete Evaluation:  When you are ready to submit quiz answers, go to the BLUE take test/evaluation button.

      Accreditation Statement

      The University of Connecticut School of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

      Pharmacists and Pharmacy Technicians are eligible to participate in this application-based activity and will receive up to 1.0 CE Hours (or 0.1 CEUs)  for completing the activity ACPE UAN 0009-0000-22-056-H01-P, passing the quiz with a grade of 70% or better, and completing an online evaluation. Statements of credit are available via the CPE Monitor online system and your participation will be recorded with CPE Monitor within 72 hours of submission.

      Grant Funding

      There is no grant funding for this activity.

      Faculty

      C. Michael White, PharmD, FCCP, FCP
      BOT Distinguished Professor and Chair of Pharmacy Practice
      University of Connecticut School of Pharmacy
      Storrs, CT              

      Faculty Disclosure

      In accordance with the Accreditation Council for Pharmacy Education (ACPE) Criteria for Quality and Interpretive Guidelines, The University of Connecticut School of Pharmacy requires that faculty disclose any relationship that the faculty may have with commercial entities whose products or services may be mentioned in the activity.

      • Dr. White has no relationships with ineligible companies

      Disclaimer

      The material presented here does not necessarily reflect the views of The University of Connecticut School of Pharmacy or its co-sponsor affiliates. These materials may discuss uses and dosages for therapeutic products, processes, procedures and inferred diagnoses that have not been approved by the United States Food and Drug Administration. A qualified health care professional should be consulted before using any therapeutic product discussed. All readers and continuing education participants should verify all information and data before treating patients or employing any therapies described in this continuing education activity.

      Content

      Post Test

      Mary Maple is an 80-year old with angina pectoris, what intensity of statin therapy should she receive and how much should her LDL be reduced?
      a) Moderate intensity, 30%
      b) High intensity, 50%
      c) Low intensity, 20%

      Mary Maple is an 55-year old with angina pectoris, what intensity of statin therapy should she receive and how much should her LDL be reduced?
      a) Moderate intensity, 30%
      b) High intensity, 50%
      c) Low intensity, 20%

      According to the CTT relationship, whether the intensity of statin was increased or adjunctive therapy with ezetimibe or evolocumab was used, the relationship between LDL lowering and cardiovascular event reduction had the same relationship
      a) True
      b) False

      Does the CTT relationship apply to inclisirin and bempedoic acid or just to statins, ezetimibe, and PCSK9 inhibitors?
      a) Yes
      b) Unknown
      c) No

      Which of the following describes the mechanism of action correctly?
      a) Inclisiran inhibits the formation of PCSK9 by inserting small interfering RNA into the cell
      b) Bempedoic acid blocks the binding of PCSK9 to the LDL receptor
      c) Both of the mechanisms are described correctly

      Which of the new cholesterol reducing drugs can cause tendon rupture and increased uric acid?
      a. Inclisiran
      b. Bempedoic acid
      c. Both agents

      Which of the following agents can be given every six months once steady state concentrations are achieved?
      a. Inclisiran
      b. Bempedoic acid
      c. Both agents

      Hypertrophic cardiomyopathy can lead to what adverse events?
      a. Atrial and ventricular arrhythmias
      b. Stroke
      c. Both of these issues

      Mavacamten might be able to replace which of the following HCM treatments?
      a. Beta-blockers of Non-DHP CCBs
      b. ICDs or anticoagulants
      c. Disopyramide or septal reduction therapies

      Mavacamten should not be used if the left ventricular ejection fraction goes below what value?
      a. 20%
      b. 30%
      c. 40%
      d. 50%

      Handouts

      VIDEO

      Law: Tic-Toc, Turn Back the Clock: Pharmacy in the Post-Roe v. Wade Climate-RECORDED WEBINAR

      About this Course

      This course is a recorded (home study version) of the CE Finale Encore Webinars.

       

      Learning Objectives

      Upon completion of this application based CE Activity, a pharmacist will be able to:

      1.       Review the original Roe v. Wade ruling and its impact on healthcare in the United States
      2.       Discuss Dobbs v. Jackson Women’s Health Organization and its impact on Roe v. Wade
      3.       Identify the implications of these Supreme Court rulings on pharmacy practice

      Release and Expiration Dates

      Released:  December 16, 2022
      Expires:  December 16, 2025

      Course Fee

      $17 Pharmacist

      ACPE UAN

      0009-0000-22-057-H03-P

      Session Code

      22RW57-JXT85

      Accreditation Hours

      1.0 hours of CE

      Additional Information

       

      How to Complete Evaluation:  When you are ready to submit quiz answers, go to the BLUE take test/evaluation button.

      Accreditation Statement

      The University of Connecticut School of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

      Pharmacists and Pharmacy Technicians are eligible to participate in this application-based activity and will receive up to 1.0 CE Hours (or 0.1 CEUs)  for completing the activity ACPE UAN 0009-0000-22-057-H03-P, passing the quiz with a grade of 70% or better, and completing an online evaluation. Statements of credit are available via the CPE Monitor online system and your participation will be recorded with CPE Monitor within 72 hours of submission.

      Grant Funding

      There is no grant funding for this activity.

      Faculty

      Kelsey Giara, PharmD
      Freelance Medical Writer
      Pelham, NH

      Faculty Disclosure

      In accordance with the Accreditation Council for Pharmacy Education (ACPE) Criteria for Quality and Interpretive Guidelines, The University of Connecticut School of Pharmacy requires that faculty disclose any relationship that the faculty may have with commercial entities whose products or services may be mentioned in the activity.

      • Kelsey Giara has no relationships with ineligible companies

      Disclaimer

      The material presented here does not necessarily reflect the views of The University of Connecticut School of Pharmacy or its co-sponsor affiliates. These materials may discuss uses and dosages for therapeutic products, processes, procedures and inferred diagnoses that have not been approved by the United States Food and Drug Administration. A qualified health care professional should be consulted before using any therapeutic product discussed. All readers and continuing education participants should verify all information and data before treating patients or employing any therapies described in this continuing education activity.

      Content

      Post Test

      Pharmacist Post-test

      Learning Objectives
      After completing this continuing education activity, pharmacists will be able to
      • REVIEW the original Roe v. Wade ruling and how it impacted healthcare in the United States
      • DISCUSS Dobbs v. Jackson Women’s Health Organization and its impact on Roe v. Wade
      • IDENTIFY the implications of these Supreme Court rulings on pharmacy practice

      1. What did the original Roe v. Wade ruling do?
      A. Made abortion legal in the U.S. at any gestational age for any reason
      B. Left it up to individual states in the U.S. to regulate abortion at any gestational age
      C. Made abortion legal in the U.S. through the first trimester of pregnancy

      2. What did the Planned Parenthood of Southeastern Pennsylvania v. Casey ruling do?
      A. Overturned Roe v. Wade and made abortion illegal across the U.S.
      B. Provided states the ability to pass more restrictive laws regarding abortion
      C. Laid the groundwork for Dobbs v. Jackson Women’s Health Organization

      3. What did the Dobbs v. Jackson Women’s Health Organization ruling do?
      A. Made abortion illegal in the U.S. at any gestational age for any reason
      B. Left it up to individual states in the U.S. to regulate abortion at any gestational age
      C. Made abortion illegal in the U.S. after the first trimester of pregnancy

      4. Which of the following was the first successful 6-week abortion ban after the Roe v. Wade ruling?
      A. Gestational Age Act
      B. Partial-Birth Abortion Ban
      C. Heartbeat Act

      5. Which of the following states would be MOST likely to enforce abortion bans through criminal penalties?
      A. Tennessee
      B. New Mexico
      C. Florida

      6. Which of the following is TRUE about EMTALA?
      A. It effectively supersedes state law regarding abortion
      B. It states that providers must abort ectopic pregnancies
      C. It is not enforceable in the case of abortion care

      7. Which of the following is TRUE about dispensing intramuscular methotrexate following the overturn of Roe v. Wade?
      A. Pharmacists should use clinical judgment to practice corresponding responsibility and follow state laws
      B. It is illegal to dispense to a woman of childbearing age unless they have documented psoriatic arthritis
      C. Refusing to fill for any reason is illegal, and pharmacists will face fines and imprisonment for discrimination

      8. Which of the following is the BEST way to prevent discrimination or perceived discrimination?
      A. Ask all women of childbearing age about pregnancy status when they fill teratogenic medications
      B. Decline to fill all prescriptions for abortifacient medications for women of childbearing age
      C. Ask individuals about their religious beliefs before offering them employment

      9. Which of the following is TRUE about federal preemption?
      A. It requires physicians to use telehealth to prescribe medication abortion drugs if patients request
      B. It supersedes the FDA to prohibit providers from prescribing opioids to women of childbearing age
      C. The Women’s Health Protection Act of 2021 may provide federal preemption regarding abortion services

      10. A woman presents to the emergency department at your hospital experiencing complications related to a miscarriage during the ninth week of pregnancy. You work in a state where a 6-week abortion ban is in effect, and a provider suspects the individual of having taken medication to end their pregnancy. A coworker insists on reporting this information to authorities because she does not want to be liable for withholding the information from law enforcement. The law does not require the hospital to report individuals to law enforcement for intentionally ending a pregnancy, but your coworker states that the HIPAA Privacy Rule allows this kind of disclosure. What should you do?
      A. Assure your coworker that reporting this patient to law enforcement is an unlawful disclosure of PHI
      B. Let your coworker report this information to law enforcement and then report your coworker for PHI disclosure
      C. Report this patient to law enforcement so that you are not held liable if she is later charged with unlawful abortion

      Handouts

      VIDEO

      LAW: Legal Perspectives on New and Evolving Issues in Pharmacy-RECORDED WEBINAR

      About this Course

      This course is a recorded (home study version) of the CE Finale Encore Webinars.

       

      Learning Objectives

      Upon completion of this application based CE Activity, a pharmacist will be able to:

      1. Describe recent industry trends and regulatory actions affecting pharmacists’ workplace conditions
      2. Explain how a refusal to fill a legitimate prescription might result in civil liability
      3. Identify emerging approaches to containing the cost of drugs

      Release and Expiration Dates

      Released:  December 16, 2022
      Expires:  December 16, 2025

      Course Fee

      $17 Pharmacist

      ACPE UAN

      0009-0000-22-054-H03-P

      Session Code

      22RW54-ABC28

      Accreditation Hours

      1.0 hours of CE

      Additional Information

       

      How to Complete Evaluation:  When you are ready to submit quiz answers, go to the BLUE take test/evaluation button.

      Accreditation Statement

      The University of Connecticut School of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

      Pharmacists and Pharmacy Technicians are eligible to participate in this application-based activity and will receive up to 1.0 CE Hours (or 0.1 CEUs)  for completing the activity ACPE UAN 0009-0000-22-054-H03-P, passing the quiz with a grade of 70% or better, and completing an online evaluation. Statements of credit are available via the CPE Monitor online system and your participation will be recorded with CPE Monitor within 72 hours of submission.

      Grant Funding

      There is no grant funding for this activity.

      Faculty

      Jennifer A. Osowiecki, RPh, JD
      Cox & Osowiecki, LLC
      Suffield, Connecticut  

      Faculty Disclosure

      In accordance with the Accreditation Council for Pharmacy Education (ACPE) Criteria for Quality and Interpretive Guidelines, The University of Connecticut School of Pharmacy requires that faculty disclose any relationship that the faculty may have with commercial entities whose products or services may be mentioned in the activity.

      • Attorney Osowiecki has no relationships with ineligible companies

      Disclaimer

      The material presented here does not necessarily reflect the views of The University of Connecticut School of Pharmacy or its co-sponsor affiliates. These materials may discuss uses and dosages for therapeutic products, processes, procedures and inferred diagnoses that have not been approved by the United States Food and Drug Administration. A qualified health care professional should be consulted before using any therapeutic product discussed. All readers and continuing education participants should verify all information and data before treating patients or employing any therapies described in this continuing education activity.

      Content

      Post Test (for viewing only)

      Post Test

      Legal Perspectives on New and Evolving Issues in Pharmacy
      Post-test
      At the conclusion of this CPE activity, participants should be able to:
      1. Describe recent industry trends and regulatory actions affecting pharmacists’ workplace conditions
      2. Explain how a refusal to fill a legitimate prescription might result in civil liability
      3. Identify emerging approaches to containing the cost of drugs

      1. When thinking about health-system pharmacists who participated in a survey of well-being, which of the following is TRUE?
      A. The majority of pharmacists indicated that their organizations offered resources to improve well-being and that they had used the resources.
      B. Pharmacists who had a greater number of non-clinical duties were least likely to report negative effects on well-being.
      C. Only a small percentage of these pharmacists—14.5%—were aware of resources offered by their organizations that could help improve well-being.

      2. When reading stories published in various newspapers across the country, which of the following may be a limitation in their findings?
      A. The people who conducted the “research” are not pharmacists.
      B. The “data” is not collected in a structured, evidence-based way.
      C. The newspapers rarely fact-check information before publishing.

      3. A patient presents a prescription for emergency contraception on a Saturday evening. The sole pharmacist on duty refuses to fill it based on his religious beliefs and says he will also be the only pharmacist on duty on Sunday and Monday. Which of the following actions may INCREASE the likelihood of civil litigation?
      A. The pharmacist tells the patient nothing other than he belongs to a religious sect that considers emergency contraception an abortifacient and he will not fill it.
      B. The pharmacist tells the patient that the chain pharmacy across the street is open for another two hours, stocks the medication, and can fill the prescription.
      C. The pharmacist asks the patient if she would like him to call his coworker and ask the coworker to come in within 24 hours to fill this prescription.

      4. Which of the following prescriptions (which pharmacists refused to fill to treat COVID) resulted in a lawsuit against Walmart and Hy-vee pharmacies that was ultimately dismissed?
      A. ivermectin and hydroxychloroquine
      B. sodium hyochlorite and ivermectin
      C. hydroxychloroquine and molnupiravir

      5. Which of the following would reduce prescription drug costs for Medicare patients?
      A. The 340B Program
      B. Price disrupters and PBMs
      C. Inflation Reduction Act of 2022

      6. Which of the following terms and descriptions are matched correctly?
      A. Clear Bagging: Having the health system’s specialty pharmacy fill the prescription and transport it directly to the place where it will be given.
      B. Brown Bagging: Having a specialty pharmacy ship a medication directly to the hospital or clinic so it can be administered to the patient there.
      C. Gold Bagging: Having a patient fill a prescription by whatever means available and bring it to the hospital or doctor’s office for administration.

      Handouts

      VIDEO

      What in the World: A Global Look at Healthcare and Drugs-RECORDED WEBINAR

      About this Course

      This course is a recorded (home study version) of the CE Finale Encore Webinars.

       

      Learning Objectives

      Upon completion of this application based CE Activity, a pharmacist will be able to:

      1.       Describe the key components of global healthcare systems
      2.       Discuss the performance indicators of global health systems
      3.       Compare pharmaceutical drug spending levels and trends globally
      4.       Define medical tourism and analyze its associated risks and benefits

      Release and Expiration Dates

      Released:  December 16, 2022
      Expires:  December 16, 2025

      Course Fee

      $17 Pharmacist

      ACPE UAN

      0009-0000-22-055-H04-P

      Session Code

      22RW55-CBA96

      Accreditation Hours

      1.0 hours of CE

      Additional Information

       

      How to Complete Evaluation:  When you are ready to submit quiz answers, go to the BLUE take test/evaluation button.

      Accreditation Statement

      The University of Connecticut School of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

      Pharmacists and Pharmacy Technicians are eligible to participate in this application-based activity and will receive up to 1.0 CE Hours (or 0.1 CEUs)  for completing the activity ACPE UAN 0009-0000-22-055-H04-P, passing the quiz with a grade of 70% or better, and completing an online evaluation. Statements of credit are available via the CPE Monitor online system and your participation will be recorded with CPE Monitor within 72 hours of submission.

      Grant Funding

      There is no grant funding for this activity.

      Faculty

      Bisni Narayanan, PharmD
      Outpatient Pharmacy Services
      Yale New Haven Health System
      Pharmacy Supervisor- Operations
      Hamden, CT

      Faculty Disclosure

      In accordance with the Accreditation Council for Pharmacy Education (ACPE) Criteria for Quality and Interpretive Guidelines, The University of Connecticut School of Pharmacy requires that faculty disclose any relationship that the faculty may have with commercial entities whose products or services may be mentioned in the activity.

      • Dr. Narayanan has no relationships with ineligible companies

      Disclaimer

      The material presented here does not necessarily reflect the views of The University of Connecticut School of Pharmacy or its co-sponsor affiliates. These materials may discuss uses and dosages for therapeutic products, processes, procedures and inferred diagnoses that have not been approved by the United States Food and Drug Administration. A qualified health care professional should be consulted before using any therapeutic product discussed. All readers and continuing education participants should verify all information and data before treating patients or employing any therapies described in this continuing education activity.

      Content

      Post Test

      World Health Post Test – CE Finale

      After completing this continuing education activity, pharmacists will be able to
      1. Describe the key components of global healthcare systems
      2. Discuss the performance indicators of global health systems
      3. Compare pharmaceutical drug spending levels and trends globally
      4. Define medical tourism and analyze its associated risks and benefits

      Which of the following are key components in global health systems?

      a. Wait times, patient satisfaction, propensity to result in personal bankruptcy, number of healthcare professionals employed, accreditation

      b. Type of ownership (public vs. private), patient’s financial obligations, extent of coverage (e.g., preventive, inpatient, outpatient care, etc.)

      c. Antibiotic resistance, risk of exposure to blood borne diseases, long distance travel, exposure to unusual infections

      What is a common problem encountered in the universal payer model that is frequently used as a performance measure?

      a. High out of pocket cost of care

      b. Long wait times

      c. Higher mortality rates

      In comparison to other high-income countries, where does the U.S system’s administrative efficiency rank?

      a. 9th

      b. 10th

      c. 11th

      A student under your supervision is filling a prescription for a newly approved drug. She asks if it is a biologic and you say no, it is a drug (also called a small molecule) and explain the difference between a drug and a biologic, most of which are specialty medications. She says that she heard that long patent lives on innovative drugs fuel pharmaceutical drug spending. What do you tell her?

      a. “You are incorrect. The largest contributor to increased spending for pharmaceuticals is specialty medications”

      b. “You are incorrect. The largest contributor to increased spending for pharmaceuticals is COVID-19 therapeutics.”

      c. “You are incorrect. The largest contributor to increased spending for pharmaceuticals is over the counter medications.”

      Handouts

      VIDEO

      First-Line Medication Therapy for Type 2 Diabetes: Time for a Change? -RECORDED WEBINAR

      About this Course

      This course is a recorded (home study version) of the CE Finale Encore Webinars.

       

      Learning Objectives

      Upon completion of this application based CE Activity, a pharmacist will be able to:

      1.      List the American Diabetes Association’s recommended approach to preventing diabetes-related long-term complications.
      2.      Identify efficacy and safety data for the newest FDA-approved diabetes medication.
      3.      Recall the most recent ADA’s guideline recommendations on medication management of hyperglycemia in type 2 diabetes.

      Release and Expiration Dates

      Released:  December 16, 2022
      Expires:  December 16, 2025

      Course Fee

      $17 Pharmacist

      ACPE UAN

      0009-0000-22-058-H01-P

      Session Code

      22RW58-VXK92

      Accreditation Hours

      1.0 hours of CE

      Additional Information

       

      How to Complete Evaluation:  When you are ready to submit quiz answers, go to the BLUE take test/evaluation button.

      Accreditation Statement

      The University of Connecticut School of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

      Pharmacists and Pharmacy Technicians are eligible to participate in this application-based activity and will receive up to 1.0 CE Hours (or 0.1 CEUs)  for completing the activity ACPE UAN 0009-0000-22-058-H01-P, passing the quiz with a grade of 70% or better, and completing an online evaluation. Statements of credit are available via the CPE Monitor online system and your participation will be recorded with CPE Monitor within 72 hours of submission.

      Grant Funding

      There is no grant funding for this activity.

      Faculty

      Khanh Dang, PharmD, CDCES, FNAP
      Associate Clinical Professor
      UConn School of Pharmacy
      Storrs, CT

      Faculty Disclosure

      In accordance with the Accreditation Council for Pharmacy Education (ACPE) Criteria for Quality and Interpretive Guidelines, The University of Connecticut School of Pharmacy requires that faculty disclose any relationship that the faculty may have with commercial entities whose products or services may be mentioned in the activity.

      • Dr. Dang has no relationships with ineligible companies

      Disclaimer

      The material presented here does not necessarily reflect the views of The University of Connecticut School of Pharmacy or its co-sponsor affiliates. These materials may discuss uses and dosages for therapeutic products, processes, procedures and inferred diagnoses that have not been approved by the United States Food and Drug Administration. A qualified health care professional should be consulted before using any therapeutic product discussed. All readers and continuing education participants should verify all information and data before treating patients or employing any therapies described in this continuing education activity.

      Content

      Post Test

      Post Test

      First-Line Therapy for Type 2 Diabetes: Time for a Change?

      1. What is the MOST IMPORTANT therapeutic goal in the management of diabetes?
      a. Reduce the A1c to <7%
      b. Prevent the development of long-term complications of diabetes
      c. Save money from costly treatments

      2. What is the most common cause of mortality in people with uncontrolled type 2 diabetes?
      a. Complications of atherosclerotic cardiovascular disease
      b. Neuropathic pain
      c. Diabetic eye disease

      3. Tirzepatide belongs to which of the following drug class?
      a. GLP-1 receptor agonists
      b. Dual GIP/GLP-1 receptor agonist
      c. SGLT2 inhibitors

      4. Mr. N, the hypothetical patient from the presentation, is prescribed tirzepatide by his PCP. Which of the following would be expected as a COMMON side effect of tirzepatide?
      a. Pancreatitis
      b. Neuropathic pain
      c. Nausea

      5. Which of the following statements is TRUE according to the 2023 American Diabetes Association’s diabetes guidelines?
      a. Four areas are equally emphasized: glycemic management, weight management, cardiovascular risk factor management, and cardiorenal protection.
      b. Glycemic control is the most important therapeutic goal and prescribers should encourage all patient to strive for a HbA1c lower than 6.
      c. Prevention of kidney complications of diabetes should be emphasized above other management strategies.

      6. Which of the following drug class is associated with the LOWEST potential for weight loss (hint: see the tables at the end of the presentation)?
      a. Biguanide (metformin)
      b. SGLT2 inhibitors
      c. GLP-1 receptor agonists

      Handouts

      VIDEO

      Over the Counter Hearing Aids: Breaking Sound Barriers in Community Pharmacy-RECORDED WEBINAR

      About this Course

      This course is a recorded (home study version) of the CE Finale Encore Webinars.

       

      Learning Objectives

      Upon completion of this knowledge based CE Activity, a pharmacist will be able to:

      1. Describe the signs and symptoms of mild to moderate hearing loss 
      2. Recognize how patient-specific barriers restrict access to hearing health care  
      3. Discuss strategies to assist patients with appropriate OTC hearing aid selection 

      Release and Expiration Dates

      Released:  December 16, 2022
      Expires:  December 16, 2025

      Course Fee

      $17 Pharmacist

      ACPE UAN

      0009-0000-22-060-H01-P

      Session Code

      22RW60-XYW84

      Accreditation Hours

      1.0 hours of CE

      Additional Information

       

      How to Complete Evaluation:  When you are ready to submit quiz answers, go to the BLUE take test/evaluation button.

      Accreditation Statement

      The University of Connecticut School of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

      Pharmacists and Pharmacy Technicians are eligible to participate in this knowledge-based activity and will receive up to 1.0 CE Hours (or 0.1 CEUs)  for completing the activity ACPE UAN 0009-0000-22-060-H01-P, passing the quiz with a grade of 70% or better, and completing an online evaluation. Statements of credit are available via the CPE Monitor online system and your participation will be recorded with CPE Monitor within 72 hours of submission.

      Grant Funding

      There is no grant funding for this activity.

      Faculty

      Katherine MacDonald, PharmD
      Pharmacist
      UConn Student Health & Wellness
      Storrs, CT

      Faculty Disclosure

      In accordance with the Accreditation Council for Pharmacy Education (ACPE) Criteria for Quality and Interpretive Guidelines, The University of Connecticut School of Pharmacy requires that faculty disclose any relationship that the faculty may have with commercial entities whose products or services may be mentioned in the activity.

      • Dr. MacDonald has no relationships with ineligible companies

      Disclaimer

      The material presented here does not necessarily reflect the views of The University of Connecticut School of Pharmacy or its co-sponsor affiliates. These materials may discuss uses and dosages for therapeutic products, processes, procedures and inferred diagnoses that have not been approved by the United States Food and Drug Administration. A qualified health care professional should be consulted before using any therapeutic product discussed. All readers and continuing education participants should verify all information and data before treating patients or employing any therapies described in this continuing education activity.

      Content

      Post Test

      Post Test

      1.Which of the following symptoms is indicative of mild to moderate hearing loss

       

      1. Recent treatment for an ear infection
      2. Difficulty maintaining conversation in quiet environments
      3. Watching TV with subtitles on

       

        

      1. M.M., a 75-year-old female, arrives at the pharmacy to pick up her celecoxib prescription (which she takes for arthritis) and to return the ITC-style OTC hearing aids she purchased two weeks ago. When you ask why she's returning the hearing devices, she expresses that she "doesn't need them" as much as she thought, then adds "they feel ok when they're in, but I'm nervous that like they're going to just pop out of my head." Which alternative style of OTC hearing aid might better address M.M.'s needs and priorities?

       

      1. Completely-in-Canal
      2. Behind-the-Ear
      3. Personal Sound Amplification Product

       

      3.D.J. is a regular patient at your pharmacy; today he's joined by his niece. You know that he has difficulty hearing, especially in the busy pharmacy, and make a mental note to remove your mask and speak slowly while you're talking to him. As D.J. and his niece wait for his prescription to be filled, D.J.'s niece points out the OTC hearing aid display by the counter and suggests that "something like that would be perfect for you!" D.J. remarks that he "isn't some bionic action figure and can hear just fine." What is D.J.'s greatest barrier to accessing OTC hearing aids? 

       

      1. Severe hearing loss
      2. No perceived need
      3. Accessibility

       

      1. Which medication is most likely to cause hearing loss?
      2. Gentamycin
      3. Hydrochlorothiazide 
      4. Ibuprofen 
      5. Methotrexate 

       

       

      1. C.S. is a 72-year-old female with moderate hearing loss. Her past medical history also includes diabetes and recent total knee replacement surgery. After her knee replacement, she moved into assisted living and “is excited to meet more of my neighbors and maybe even sign up for a pottery class.” C.S. noticed that OTC hearing aids are available at her local pharmacy and believes that they could help her be more involved in her new community. Which of the following patient-specific characteristics will influence the outcomes of OTC hearing aid use?

       

      1. Limited mobility 
      2. Age
      3. Self-efficacy

       

       

      1. Individuals with untreated hearing loss are more likely to experience which of the following?
      2. Social isolation
      3. Improved cognition
      4. Reversible hearing loss

       

       

      1. Pharmacists are expected to play a new and important role as healthcare providers as hearing aids hit the shelves of community pharmacies. Which of the following best describes how pharmacists will participate in OTC hearing aid provision?

       

      1. Diagnose underlying causes of hearing loss
      2. Administer hearing tests to interested individuals
      3. Employ effective communication strategies

       

       

       

      Handouts

      VIDEO

      Immunization: Is Winter Here? – An Update on Monkey Pox and Covid Vaccines-RECORDED WEBINAR

      About this Course

      This course is a recorded (home study version) of the CE Finale Encore Webinars.

       

      Learning Objectives

      Upon completion of this application based CE Activity, a pharmacist will be able to:

      1. Discuss trends in the epidemiology of the COVID-19 pandemic and Monkeypox outbreak.
      2. Discuss current clinical data on the safety and effectiveness of (i) the bivalent COVID-19 booster vaccines and (ii) the JYNNEOS or ACAM2000 vaccines for Monkeypox.
      3. Explain whether a person would be eligible for receipt of (i) the bivalent COVID-19 booster vaccines and/or (ii) the JYNNEOS or ACAM2000 vaccines for Monkeypox.

      Release and Expiration Dates

      Released:  December 16, 2022
      Expires:  December 16, 2025

      Course Fee

      $17 Pharmacist

      ACPE UAN

      0009-0000-22-059-H06-P

      Session Code

      22RW59-KXV39

      Accreditation Hours

      1.0 hours of CE

      Additional Information

       

      How to Complete Evaluation:  When you are ready to submit quiz answers, go to the BLUE take test/evaluation button.

      Accreditation Statement

      The University of Connecticut School of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

      Pharmacists and Pharmacy Technicians are eligible to participate in this application-based activity and will receive up to 1.0 CE Hours (or 0.1 CEUs)  for completing the activity ACPE UAN 0009-0000-22-059-H06-P, passing the quiz with a grade of 70% or better, and completing an online evaluation. Statements of credit are available via the CPE Monitor online system and your participation will be recorded with CPE Monitor within 72 hours of submission.

      Grant Funding

      There is no grant funding for this activity.

      Faculty

      Jeffery Aeschlimann, PharmD
      Associate Clinical Professor-Infectious Disease Specialty
      University of Connecticut School of Pharmacy
      Storrs, CT  

      Faculty Disclosure

      In accordance with the Accreditation Council for Pharmacy Education (ACPE) Criteria for Quality and Interpretive Guidelines, The University of Connecticut School of Pharmacy requires that faculty disclose any relationship that the faculty may have with commercial entities whose products or services may be mentioned in the activity.

      • Dr. Aeschlimann has no relationships with ineligible companies

      Disclaimer

      The material presented here does not necessarily reflect the views of The University of Connecticut School of Pharmacy or its co-sponsor affiliates. These materials may discuss uses and dosages for therapeutic products, processes, procedures and inferred diagnoses that have not been approved by the United States Food and Drug Administration. A qualified health care professional should be consulted before using any therapeutic product discussed. All readers and continuing education participants should verify all information and data before treating patients or employing any therapies described in this continuing education activity.

      Content

      Post Test

       

      1. Good news! News reporters and Internet sites began announcing in the spring and summer of 2022 that the global pandemic had ended.  What do you think of that?
        1. YAY! Science prevailed and we obliterated that bad boy and sent it away!
        2. FAKE NEWS. Approximately 2,000 Americans still die each week from (or with) active COVID-19 disease.
        3. CORRECT, but COVID is still a major concern in our socially inclined young adults.

       

      1. What does the data say about adverse effects associated with the bivalent COVID-19 boosters?
        1. The most common adverse effects are systemic (fever, chills, fatigue)
        2. The most common adverse effects are central (headache, mental fogginess)
        3. The most common adverse effects are local (pain, erythema, swelling)

       

      1. Based on current vaccination statistics about populations that have the poorest booster coverage for COVID-19, which of the following population should pharmacists be encouraging to GET VACCINATED!?!
        1. Children age 5 or younger in the Great Lakes regions
        2. People older than 65 in the Pacific northwest
        3. Everybody everywhere
        4. Monkeypox is the name and name-changing is the game. What has the World Health organization decided to call this infection and why?
        5. It will be monk's disease, which will remove some of the stigmatizing language and remind people to live like a monk until the lesions disappear.
        6. It will be mpox, which is intended to dissuade people from using racist and stigmatizing language to describe people infected with this virus.
        7. It will be var-vac-human, reflecting its similarity to variola (smallpox) and vaccinia (viral vaccine for smallpox) and its zoonotic transmission.

       

       

      1. What is eczema vaccinatum?
      2. A complication of the ACAM2000 vaccination that can occur in patients who have eczema/atopic dermatitis, in which vaccinia virus disseminates to cause an extensive rash and systemic illness.
      3. A complication of the JYNNEOS vaccination that can occur in patients who have eczema/atopic dermatitis, in which vaccinia virus disseminates to cause an extensive rash and systemic illness.
      4. A complication of the ACAM2000 vaccination that can occur in patients who have any chronic skin condition, in which vaccinia virus disseminates to cause an extensive rash and systemic illness.

       

       

      1. Andi is a person living with HIV infection who also is prone to keloids. This patient wants the JYNNEOS vaccination for mpox. What is the best course of action?
        1. Administer the vaccine intradermally
        2. Administer the vaccine subcutaneously
        3. Recommend using ACAM2000 instead

       

       

      Handouts

      VIDEO